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THE POLICY REPORT
Steven Wooding, Stephen Hanney, Alexandra Pollitt,  
Martin Buxton and Jonathan Grant  
on behalf of the Project Retrosight TeamPreface
This report1 describes a case study-based review 
of 29 cardiovascular and stroke research grants, 
funded in three countries between 1989 and 1993. 
The case studies focused on the individual grants 
but considered the development of the investiga-
tors and ideas involved in the research projects 
from initiation to the present day. Basic biomedi-
cal and clinical cardiovascular and stroke research 
grants awarded in Australia, Canada and the UK 
were selected through a stratified random selec-
tion approach that aimed to include both high- 
and low-impact grants. The structured case studies 
were used to assess the impact of these grants in 
detail and to draw conclusions about the relation-
ship between impact and a range of factors. The 
key messages are as follows.
•	 The cases reveal that a large and diverse range 
of impacts arose from the 29 grants studied.
•	 There are variations between the impacts 
derived from basic biomedical and clinical 
research.
•	 There is no correlation between knowledge 
production and wider impacts.
•	 The majority of economic impacts identified 
come from a minority of projects.
•	 We identified factors that appear to be associ-
ated with high and low impact.
This report presents the key observations of the 
study and an overview of the methods involved. 
It has been written for funders of biomedical   
and health research and health services, health 
researchers, and policy makers in those fields.   
It will also be of interest to those involved in 
research and impact evaluation. The accompanying  
1  This study was supported by an international collaboration of 
research funders. Please see the Acknowledgements, page xiii, for 
details.
Methodology Report2 presents the methods used 
in more detail and the Case Study Report3 presents 
all 29 case studies that were carried out.
This work was led by RAND Europe in col-
laboration with the Health Economics Research 
Group (HERG) at Brunel University. RAND 
Europe is an independent not-for-profit policy 
research organisation that serves the public inter-
est by improving policy making and informing 
public debate. The Health Economics Research 
Group is a Specialist Research Institute of Brunel 
University dedicated to conducting accessible, 
policy-relevant research of a high academic qual-
ity that is focused on improving the efficiency and 
cost-effectiveness of resources devoted to health 
care and to research. This report has been peer-
reviewed in accordance with RAND’s quality 
assurance standards4 and therefore may be repre-
sented as a RAND Europe product.
For more information about RAND Europe or 
this document, please contact
Steven Wooding
Research Leader
RAND Europe
Westbrook Centre, Milton Road
Cambridge, CB4 1YG
United Kingdom
Email: wooding@rand.org or reinfo@rand.org
2  Pollitt, A., S. Wooding, S. Hanney, M. Buxton and J. Grant. 
Project Retrosight. Understanding the returns from cardiovascular 
and stroke research: Methodology Report. Cambridge, UK: RAND 
Europe, TR-925-RS, 2011.
3  Pollitt, A., S. Wooding, S. Hanney, M. Buxton and J. Grant. 
Project Retrosight. Understanding the returns from cardiovascular and 
stroke research: Case Studies. Cambridge, UK: RAND Europe, TR-
926-RS, 2011.
4  RAND Europe: see http://www.rand.org/about/standards/ 
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All funders have more opportunities for investment 
in research than they can support, many of which 
relate to areas of science of high potential interest 
and/or impact. How best to choose between these 
is a key issue for funders, the scientific community, 
governments and society. The “science of science” 
is a growing field that aims to understand what 
works in research funding.5 This requires a better 
understanding of research performance, and more 
importantly the drivers of improved performance. 
At a conceptual level we need to understand what 
factors lead to research impact. For example, what 
kinds of science, what kinds of scientists, and what 
settings are most conducive to ensuring the sci-
entific success of research and its translation into 
societal benefits?
Project Retrosight
Project Retrosight was a multinational study that 
investigated the translation of, and payback from, 
basic biomedical and clinical cardiovascular and 
stroke research projects. The main project aims 
were to:
•	 examine the variety of payback produced by 
basic biomedical and clinical cardiovascular 
and stroke research;
•	 identify factors associated with high (and low) 
levels of payback, in particular factors relating 
to the characteristics of the research, how it 
was supported or the context in which it was 
carried out.
5  Marburger, J.H. “Wanted: better benchmarks.” Science 308 
(2005): 1087. Grant, J., and S. Wooding. In search of the Holy Grail: 
understanding research success. Cambridge, UK: RAND Europe, 
OP-295-GBF, 2010.
The name Project Retrosight is derived from two 
landmark studies in science policy. The first – 
Project Hindsight (1967) – was a study sponsored 
by US Department of Defense that examined the 
incremental advances of various technologies.6 The 
second was Julius Comroe’s book, Retrospectroscope: 
Insights into Medical Discovery (1977).7 Comroe 
examined new life-saving advances in medicine 
and how they had come about. At the same time, 
in a more or less direct response to Project Hind-
sight, he worked with Robert Dripps to trace the 
research antecedents of clinical advances in car-
diovascular medicine. This study was described in 
an article in Science.8 The idea of Project Retro-
sight was to develop these ideas by tracing pro-
spectively, with the benefit of hindsight, the pay-
back and translation of funded research projects. 
Project Retrosight builds on successful meth-
odologies used to evaluate diabetes and arthritis 
research funding.9
Our approach involved identifying the princi-
pal investigators (PIs) of all grants awarded in the 
early 1990s for basic biomedical and clinical cardio-
vascular and stroke research by specific funders in 
Australia, Canada and the United Kingdom. These 
PIs were sent simple questionnaires that were used 
to estimate the impact of the work funded by the 
grant. A random sample of grants was then selected 
6  Sherwin, C.W. and R.S. Isenson. “Project Hindsight. A Defense 
Department study on the utility of research.” Science 161 (1967): 
1571–7.
7  Comroe, J.H. Retrospectroscope: insights into medical discovery. 
Menlo Park, California: Von Gehr Press, 1977.
8  Comroe, J.H. and R.D. Dripps. “Scientific basis for the support 
of biomedical science.” Science, 192 (1976): 105–11
9  Hanney, S., P. Home, I. Frame, J. Grant, P. Green and M. Buxton. 
“Identifying the impact of diabetes research.” Diabetic Medicine 23 
(2006): 176–84. Wooding, S., S. Hanney, M. Buxton and J. Grant. 
“Payback arising from research funding: Evaluation of the Arthritis 
Research Campaign.” Rheumatology 44 (2005): 1145–56.viii    Project Retrosight
policy makers, changes in policy or practice, etc. 
The case studies were then coded qualitatively and 
analysed to identify factors that appeared to be 
associated with high and low impact in both aca-
demic and wider categories. The associations that 
emerged were then tested and refined in discus-
sion with researchers, funders and policy makers, 
and developed into a series of policy implications 
for research funders. 
There are, of course, a number of limitations 
to the analysis. The number of case studies used 
in Project Retrosight can be viewed as both a 
limitation and a strength. Whilst the number of 
case studies is greater than in most other studies of 
a similar nature13, the sample size may still not be 
13  Wooding, S., S. Hanney, M. Buxton and J. Grant. “Payback 
arising from research funding: Evaluation of the Arthritis Research 
Campaign.” Rheumatology 44 (2005): 1145–56. Nason, E., B. Janta, 
G. Hastings, S. Hanney, M. O’Driscoll and S. Wooding. Health 
research – making an impact. The economic and social benefits of HRB-
funded research. Dublin: Health Research Board, 2008.
using a sampling framework stratified according to 
location of research (Canada, Australia and UK), 
type of research (basic biomedical or clinical), size 
of research grant (large or small) and perception of 
impact by the PI (high or low). Detailed case stud-
ies were then developed for 29 grants (in total we 
approached 38 cases: 6 PIs declined to participate, 
3 case studies were not completed/not included 
for other reasons). We chose a case study approach 
since, in general, case studies provide a rich source 
of material when “how” or “why” questions are 
proposed.10 In the context of Project Retrosight, 
the case studies provide a detailed picture of what 
led to establishing the grant, how the research pro-
gressed and how it subsequently developed.
A number of approaches have been developed 
to describe and capture the impacts of research.11 
We used the Payback Framework,12 which has 
two elements: five payback categories, which we 
collapsed into two impact groups for some of our 
analysis (summarised in Figure S.1); and the pay-
back model (illustrated in Figure 1.2, Chapter 
1). The Payback Framework provides a common 
structure for examining why the PI applied for the 
research grant and what he or she hoped to achieve 
with the funding; the responses of the funding 
committees; the research process, including col-
laborations, use of shared resources, etc.; research 
outputs (e.g. publications); how those outputs 
influenced subsequent research topics and careers; 
how the research was subsequently translated into 
“secondary outputs”, through influencing clini-
cal policies or product development; and how the 
research then translated into improvements in 
health and broader economic benefits. 
Examples of academic impacts included pub-
lication of papers, supervising a PhD, develop-
ing scientific methods subsequently used by 
other researchers, etc. Examples of wider impacts 
included citation in policy documents or guide-
lines, licensing intellectual property, briefing senior 
10  Yin, R.K. Case study research: design and methods (3rd ed.). Thou-
sand Oaks, CA: Sage, 2003. 
11  Brutscher, P.-B., S. Wooding and J. Grant. Health research 
evaluation frameworks. An international comparison. Cambridge, 
UK: RAND Europe, 2008. http://www.rand.org/pubs/technical_
reports/TR629 [Date accessed: 16 December 2010]
12  Buxton, M. and S. Hanney. “How can payback from health ser-
vices research be assessed?”Journal of Health Services Research and 
Policy, 1 (1996): 35-43.
Each of the case studies was developed using a range 
of data collection methods, including structured inter-
views, document and literature reviews and bibliomet-
rics. Once the fieldwork was completed, the case stud-
ies were rated by a panel of experts to identify those 
considered relatively high or low in terms of impact 
in each payback category. In the light of the correla-
tions found here between the various categories, two 
broad types of impact were defined: “academic”, i.e. 
affecting science and/or the research system; and 
“wider”, i.e. affecting broader society directly in one 
way or another. 
Payback categories
Knowledge production
Research targeting and 
capacity building
Informing policy and
product development
Health and health sector
beneﬁts
Broader economic beneﬁts
Wider
impacts
Academic
impacts
Impact groupings
Figure S.1
Payback categories and impact groupsExecutive summary    ix
Table S.1
Summary of the impacts arising from case study grants
AUSTRALIA  CANADA UK
All Australian projects produced 
peer-reviewed publications, e.g. 
a project on immunoelectron 
microscopy of amine and 
peptide synapses on sympathetic 
preganglionic neurons resulted 
in 18 articles that have received a 
total of 780 citations.
 
All Australian projects led to 
research capacity building and/
or targeting, e.g. a project on 
high density lipoprotein (HDL) led 
to collaborations for the PI and 
advanced the career of the post-
doc; it also resulted in new research 
techniques, further research 
funding for the group and better 
targeting of other groups through 
increased understanding of HDL.
 
All Australian projects contributed 
to informing policy and/or 
product development, e.g. a 
project that created animal 
models for myocardial dysfunction 
contributed to the decision to 
create a transgenic facility at the 
research institute, and eventually a 
commercial facility.
 
All Australian projects contributed 
to health gains, e.g. a project 
studying the follow-up to 
heart attacks contributed to 
a major international project 
on health promotion, which in 
turn contributed to a decline in 
coronary heart disease in the 
Hunter region.
 
Five of the eight Australian projects 
contributed to economic benefits, 
e.g. the commercial transgenic 
facility developed as a result of 
the animal models for myocardial 
dysfunction is now a multi-million-
dollar business that exports 80% of 
its services.
All Canadian projects produced 
peer-reviewed publications, e.g. 
a project on the determinants 
of increased growth of vascular 
smooth muscle in spontaneously 
hypertensive rats produced a 
series of journal articles. Sixteen 
articles produced 849 citations 
and included a paper in the highly 
prestigious Journal of Clinical 
Investigation. 
 
All Canadian projects led to 
research capacity building and/
or targeting, e.g. a project on the 
effects of simulated stroke on 
developing astrocytes led to two 
PhDs; techniques were taught.
 
Eleven of the 12 Canadian projects 
contributed to informing policy 
and/or product development, e.g. 
guidelines recommend a treatment 
pathway for antiphospholipid 
antibodies (APLA) based on the 
original warfarin-based project. 
 
 
Seven of the 12 Canadian projects 
contributed to health gains, e.g. 
the treatment path for APLA 
patients is much improved, leading 
to some health gain. 
 
 
 
 
Two of the 12 Canadian projects 
contributed to economic 
benefits, e.g. a project used a 
radioimmunoassay the PI had 
created previously: later sold by a 
commercial company.
All UK projects produced peer-
reviewed publications, e.g. a 
project on the role of coagulation 
and fibrinolysis in the pathogenesis 
of recurrent stroke led to a series of 
articles, seven of which have been 
cited 393 times in total.
 
All UK projects led to research 
capacity building and/or targeting, 
e.g. the project (above) led to two 
PhDs, an MD and development of 
a patient cohort and control group 
that formed the basis of a stream 
of work. It helped the PI establish 
his research group.
 
Four of the nine UK projects 
contributed to informing policy 
and/or product development, e.g. a 
project on stroke prevention in the 
elderly in primary care informed 
guidelines in a working group 
statement and protocols of local 
units in the health service. 
 
Four of the nine UK projects 
contributed to health gains, e.g. a 
project analysing the automated 
defibrillators in Scotland’s 
ambulances is widely cited in 
policies and made an important 
contribution to the increased 
survival rate following out-of-
hospital cardiac arrest.
 
Three of the nine UK projects 
contributed to economic benefits, 
e.g. the increased life expectancy 
of patients with Marfan syndrome 
has mostly been among people of 
working age; therefore a number 
of people have been able to remain 
active in the workforce.
large enough to rule out outcomes or differences 
that could have arisen by chance. Because of this, 
we have been deliberately cautious in interpreting 
our data and have tested the strength of any 
associations leading to policy observations. Other 
limitations include potential inconsistencies in 
case study reporting and possible confounders; for 
example, the definitions of basic biomedical and 
clinical research used, the scope of the case studies 
and the effects of negative findings. Equally there 
are significant strengths in the study method 
chosen, particularly in comparison to other 
sources of information on research funding policy. 
These strengths include the use of the Payback 
Framework to encourage consistency across 
cases and facilitate comparative analysis; quality x    Project Retrosight
assurance checks to ensure consistency across an 
international team; and consideration of both 
quantitative and qualitative case study material. 
Key findings and policy 
implications
The five key findings from the study are as follows.
1.  The cases reveal that a large and diverse range 
of impacts arose from the 29 grants studied.
2.  There are variations between the impacts 
derived from basic biomedical and clinical 
research.
3.  There is no correlation between knowledge 
production and wider impacts.
4.  The majority of economic impacts identified 
come from a minority of projects.
5.  We identified factors that appear to be associ-
ated with high and low impact.
1.  The cases reveal that a large and diverse range 
of impacts arose from the 29 grants studied
  As illustrated in Table S.1, there is a consider-
able range of research paybacks associated with 
the grants studied, and many of these would 
not have been identified without the structured, 
case study approach used in this study. This res-
onates with the diversity of payback identified 
in an earlier study on arthritis research.14
2.  There are variations between the impacts 
derived from basic biomedical and clinical 
research
  In the cases studied, basic biomedical research 
has a greater academic impact and clinical 
research a greater wider impact over the time-
scales investigated. All the grants studied 
had academic impact, but the average rating 
was higher in basic biomedical research than 
in clinical research. For the combined wider 
impact categories all clinical studies had some 
impact, compared to only six out of 15 basic 
biomedical case studies. This finding should 
be treated with caution as it may be con-
14  Wooding, S., S. Hanney, M. Buxton and J. Grant. The returns 
from arthritis research. Volume 1: Approach, analysis and recommen-
dations. Cambridge, UK: RAND Europe, MG-251-ARC, 2004.
founded by longer time lags for basic biomedi-
cal research.
 
3.  There is no correlation between knowledge 
production and wider impacts
  There is no correlation between the payback 
category, “knowledge production”, and the 
three wider categories, “informing policy and 
product development”, “health and health 
sector benefits” and “broader economic bene-
fits”. From a policy perspective this would sug-
gest that the level of knowledge production is 
not a predictor of wider impacts. 
4.  The majority of economic impacts identified 
come from a minority of projects
  Only four of the 29 case studies reported 
substantial broader economic benefits and 
19 grants had no impact in this payback cat-
egory. It is important that these distributional 
effects are understood in any assessment of 
research impact. Although the majority of 
economic impacts come from a small pro-
portion of projects, we previously found that 
the value of the impact achieved from a pro-
gramme of research overall can significantly 
outweigh the costs of doing the research.15
5.  We can identify factors that appear to be 
associated with high and low impact
  We have identified a number of factors in car-
diovascular and stroke research that are asso-
ciated with higher and lower academic and 
wider impacts. These are captured in Table S.2, 
each with an associated policy implication for 
research funders and policy makers to consider.
Just as science is the effort to discover and increase 
human understanding of how the world works 
and how we can influence it, science policy should 
be about understanding how the world of science 
works and how we can influence it to maximise 
benefits for society. Studies like Project Retrosight 
contribute to the growing field of the “science of 
science”, providing an evidence base to inform 
research funders in their decision making.
15  HERG, Office of Health Economics and RAND Europe. Medi-
cal research: what’s it worth? Esti  mating the economic benefits from 
medical research in the UK. UK Evaluation Forum, 2008.Executive summary    xi
Table S.2
Factors associated with high- and low-impact research
Factor Policy implication 
Basic biomedical research with a clear clinical 
motivation is associated with high academic and wider 
impacts
When seeking to achieve high academic and wider 
impacts, encourage and support clinically motivated basic 
biomedical research
Co-location of basic biomedical research in a clinical 
setting is associated with high wider impact
When seeking to achieve high wider impacts from basic 
biomedical research, encourage and support the co-
location of basic biomedical researchers with clinicians 
in a clinical setting (e.g. a teaching hospital or health 
organisation)
Strategic thinking by clinical researchers is associated 
with high wider impact 
When seeking to achieve high wider impacts from clinical 
research, focus clinical research funding on PIs or teams 
who think strategically about translation into clinical 
practice
Research collaboration is associated with high 
academic and wider impact
When seeking to achieve high academic and wider 
impacts, encourage and support research collaboration 
for both basic biomedical and clinical research
International collaboration is associated with high 
academic impact
When seeking to achieve high academic impact, 
encourage and support international collaboration for 
both basic biomedical and clinical research
Engagement with practitioners and patients is 
associated with high academic and wider impacts
When seeking to achieve high academic and wider 
impacts, encourage and support clinical researchers who 
have a record of engaging with practitioners and patients
Basic biomedical research collaboration with industry 
is associated with high academic and wider impacts
When seeking to achieve high academic and wider 
impacts from basic biomedical research, encourage and 
support collaboration with industry
Negative or null findings are associated with low 
academic and wider impacts
Research funders should acknowledge the importance 
and potential significance of negative or null findings 
when assessing the impact of research
Initial rejection of a subsequently accepted basic 
biomedical research grant may be associated with low 
academic and wider impacts
Further research is needed to confirm whether initial 
rejection of a research proposal is associated with low 
impact. Until this finding can be confirmed or refuted, 
funders may want to carefully consider such proposalsWe would like to start by acknowledging all those 
scientists who were willing and able to act as the 
participants for this study, particularly the princi-
pal investigators of the 29 case study grants. The 
study would clearly have been impossible without 
them.
We also owe a debt of gratitude to the   
external experts who participated in our rating 
workshop: Cy Frank, Liz Allen, Brendan Curran 
and Marcus Nichol. We would also like to   
thank those scientists who provided reviews of 
each of our case studies, and participated in our 
Emerging Findings Workshop in April 2010 in 
London.
This study was initiated with internal fund-
ing from RAND Europe and HERG, with con-
tinuing funding from the UK National Institute 
for Health Research, the Canadian Institutes of 
Health Research, the Heart and Stroke Founda-
tion of Canada and the National Heart Founda-
tion of Australia. The UK Stroke Association and 
the British Heart Foundation provided support in 
kind through access to their archives.
Project Retrosight team
Jonathan Grant (RAND Europe), Martin Buxton 
(HERG), Stephen Hanney (HERG) and Steven 
Wooding (RAND Europe) devised the method-
ological approach and analysis with input from 
the Retrosight Team. Steven Wooding managed 
and coordinated the project, supported by Eddy 
Nason (RAND Europe), Sharif Ismail (RAND 
Europe), Sue Kirk (RAND Europe) and Alex Pol-
litt (RAND Europe). Statistical analysis was pro-
vided by Laura Staetsksy (RAND Europe).
The Australian case studies were carried out 
by Rob Mercer (Instinct and Reason), Angela 
Mitchell (Instinct and Reason) and Christine 
Latif (National Heart Foundation of Australia); 
the Canadian studies by Laura McAuley (Cana-
dian Institutes of Health Research), Heather 
Mustoe (Canadian Institutes of Health Research) 
and Kimberly-Anne Ford (Canadian Institutes 
of Health Research); the UK studies by Stephen 
Hanney, Sharif Ismail, Sue Kirk, Sonja Mar-
janovic (RAND Europe) and Eddy Nason. The 
case study bibliometric analysis was coordinated 
by Linda Butler (Australian National University) 
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of society, acting as a voice for everyone affected by 
stroke. The charity funds research into prevention, 
treatment and better methods of rehabilitation; 
it helps stroke patients and their families directly 
through its community support services as well as 
providing information through its helpline, leaf-
lets and factsheets.
British Heart Foundation
The British Heart Foundation is the nation’s heart 
charity, dedicated to saving lives through pioneer-
ing research, patient care, campaigning for change 
and by providing vital information. It works along-
side government, other health charities, health 
professionals and thousands of dedicated support-
ers to beat heart disease.
University, focusing on the development of meth-
ods to assess the impact of research, with a par-
ticular expertise in bibliometric methods.
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The Centre for Science & Technology Studies 
(CWTS) is a research institute within the Leiden 
University Faculty of Social Sciences. CWTS is a 
leading research institute in the field of sciento-
metrics and bibliometrics, whose bibliometric 
techniques are frequently used in research assess-
ment procedures. CWTS’s clients include inter-
national organisations, governments and research 
groups both inside and outside the Netherlands.
Stroke Association
The Stroke Association campaigns, educates and 
informs to increase knowledge of stroke at all levels Project Retrosight addresses two key challenges 
facing those involved in supporting and fund�
ing research – understanding and predicting the 
impacts of research and how to support research�
ers in having greater impacts ��rant and �ood� ��rant and �ood�
ing, 2010). It has its home in the growing field 
of the “science of science” and seeks to shed light 
on what works in research funding �Marburger, 
2005; Macilwain, 2010). The “science of science” 
is concerned with research success and how that 
success leads to improvements, or impact, in the 
real world. It aims to understand if there are char�
acteristics that predict impact and, if so, what 
those characteristics are. It aims to discover what 
kinds of research, researcher, setting and support 
are most successful in ensuring the scientific suc�
cess of research and its translation into societal 
benefits.
The origins and aims of Project 
Retrosight
The idea that became Project Retrosight  grew 
from conversations between Martin Buxton and 
Jonathan �rant during breaks in a 1999 workshop 
on research impact organised in Banff, Canada, 
by the Alberta Heritage Foundation for Medical 
Research �now Alberta Innovates – Health Solu�
tions). The name Project Retrosight  is derived 
from two landmark studies in science policy. The 
first – Project Hindsight �Sherwin and Isenson, 
1967) – was a study sponsored by the US Depart�
ment of Defense that examined the incremental 
advances of various technologies. The second was 
Julius Comroe’s book, Retrospectroscope: Insights 
into Medical Discovery �Comroe, 1977). Comroe 
examined new life�saving advances in medicine 
and how they had came about. At the same time, 
in a more or less direct response to Project Hind�
sight, he worked with Robert Dripps to trace the 
research antecedents of clinical advances in car�
diovascular medicine. This study was described in 
an article in Science �Comroe and Drippps, 1976). 
The idea of Project Retrosight was to develop these 
ideas by tracing prospectively, with the benefit of 
hindsight, the translation of, and payback from, 
funded research projects. 
Conceived in 1999, Project Retrosight was 
several years in gestation. �ork finally started on 
the project in 2007 as a cooperation between the 
Health Economics Research �roup �HER�) at 
Brunel University and RAND Europe, with the 
support and involvement of various consortium 
members �see Acknowledgements page).
Building on successful methodologies used 
to evaluate research in diabetes �Hanney et al., 
2006) and arthritis ��ooding et al., 2005), the 
project aimed to:
•	 examine the variety of payback produced by 
basic biomedical and clinical cardiovascular 
and stroke research;
•	 identify factors associated with high �and low) 
levels of payback, in particular factors relating 
to the characteristics of the research, how it 
was supported or the context in which it was 
carried out;
•	 the significance of country context in the pro�
cess of translation and production of payback. 
Ultimately, it did not prove possible to carry 
out cross�country analysis; the reasons for this 
are discussed in the International Approach 
section on page 18.
Our intention was to contribute to the evidence 
base that describes how research translation and 
impact actually comes about, in the hope that 
the evidence could inform subsequent funding 
decisions. 
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The need to understand research
�overnments and health research charities aim 
to improve our understanding of health and   
disease, and thus population health and well being 
through basic biomedical and clinical research. 
�e consider health research to range from basic 
biomedical research through to clinical and health 
services research. There is widespread public sup�
port for health research funding ��ellcome Trust, 
2010). However, research is expensive and in 
many countries there is a growing emphasis on 
making research policies more evidence based and 
increasing accountability for research funders and 
researchers. Funding bodies are under increasing 
pressure to justify research spending by showing 
how it benefits society through improvements to 
health and economic growth. Pressure to demon�
strate the optimum use of research funds and the 
payback from research spending is further increas�
ing, partly as a result of the economic downturn in 
some countries leading to a tightening of govern�
ment expenditure ��eissberg, 2010) and pressure 
on donor contributions to charities.
This emphasis on accountability throws into 
sharp focus the major recurring challenge facing 
those involved in science and science policy: how 
best to spend research money. Although there is 
general agreement that improved knowledge and 
understanding should lead to health improvements 
and other benefits, there is little understanding of 
how this occurs.
Consequently, there is a pressing need to 
undertake studies that can shed light on how 
money spent on research is ultimately translated 
into societal benefits, including health improve�
ments, and to improve understanding of this 
translation process. Such studies aspire to take us 
beyond the many commentaries that claim there 
are benefits from research without thoroughly 
investigating how these come about �reviewed in 
Boaz et al., 2009). A recent review �Hanney et al., 
2007) of the available literature �in English) iden�
tified fewer than 50 reports describing approaches 
to evaluating the impact of health research pro�
grammes, or the empirical evaluation of a par�
ticular programme of health research. This group 
included several studies that were small in scale 
and based on limited data. So it is fair to say that 
there is an important role for further rigorous 
studies to bolster the portfolio of evidence on the 
The organisation of this report
In this chapter, we contextualise the burden of 
cardiovascular and stroke disease and discuss 
why it is important to understand the impact of 
research and to identify factors that lead to high 
levels of impact. �e outline the background to the 
Payback Framework – the conceptual framework 
we chose as the basis for the analysis in Project 
Retrosight.
Chapter 2 outlines the key stages of the 
approach we took to our research, while Chapter 
3 is a critique of our methodology, covering some 
of the key challenges the study faced and how we 
addressed them. It includes a discussion of the 
possible confounding factors in our analysis. In 
Chapter 4 we review what we see as the key mes�
sages to be drawn from the study. 
This Policy Report is accompanied by a detailed 
Methodology Report �Pollitt et al., 2011a) and 
the full case studies are available in a Case Study 
Report �Pollitt et al., 2011b).
The burden of cardiovascular and 
stroke disease
The term cardiovascular disease and stroke has 
been used throughout this report to highlight the 
notion that stroke is often considered an indepen�
dent area of research, outside the field of heart and 
blood vessel disease.
As Table 1.1 shows, cardiovascular diseases 
are leading causes of death in Australia, Canada 
and the UK, responsible for about one third of all 
deaths in all three countries. Attributable mor�
tality for stroke averages around 8%. Table 1.1 
presents a combined picture of the burden of car�
diovascular and stroke disease in three countries, 
rather than a comparison. Reported differences 
in disease prevalence among the three countries 
are due in part to differences in the age standardi�
sation method �or  lack of age standardisation); 
data collection methods �e.g. surveys plus medi�
cal records, medical records only, etc.); and char�
acteristics of samples chosen. Economic costs also 
use slightly varying definitions, which prohibit 
direct comparison. �hat is clear from Table 1.1 
is the considerable burden that cardiovascular and 
stroke disease represents for all three countries, 
and the associated importance of cardiovascular 
and stroke research. Introduction    3
Australia Canada United 
Kingdom
Mortality
Attributable mortality (CVD, all deaths)
Men
Women
Attributable mortality (CBV/stroke)
Men
Women
38%
39%
34%
9%
7%
12%
30%
31%
30%
6%
5%
8%
35%
34%
34%
11%
9%
13%
Morbidity
Prevalence in adults (CVD)
Men
Women
Prevalence in adults (CBV/stroke)
Men
Women
18%c
16%c
20%c
1%
1%
1%
5%d
5%d
4%d
1%
1%
1%
13%e
14%e
13%e
2%
2%
2%
Economic impact (converted to US dollar equivalents)
Total annual cost to national economy (all CVD)
Direct costs (treatment)
Indirect costs (loss of productivity, informal care)
Percentage of health spending (public only; direct costs of CVD)
$10.5bn
$5.6bn
$4.9bn
11%
$15.0bn
$5.1bn
$9.8bn
17%
$53.3bn
$28.8bn
$21.3bn
21%
Annual research spending (converted to US dollar equivalents)
All CVD, total spending
All CVD, spending per capita
$120.9ma
$6.01
$66.6ma
$2.38
$191.5mb
$3.20
a  Government-funded only; data from other funding sources not readily available
b  Government and major charity-funded
c   Age 14 and over
d   Age 12 and over; data from Statistics Canada’s Canadian Community Health Survey (CCHS) which measures self-
reported accounts of ‘heart disease’, and does not include CBV
e  Age 16 and over
Sources:
Australia: Heart, stroke and vascular diseases: Australian facts 2004. Canberra: Australian Institute of Health and 
Welfare, 2004; National Health Survey: Summary of Results, Australia, 2004–05 cat. no 4364.0. Australian Bureau 
of Statistics, 2006; Vos, T. and Begg, S. The burden of cardiovascular disease in Australia for the year 2003 (revised 
2007). Centre for Burden of Disease and Cost-effectiveness, University of Queensland School of Population Health. 
National Heart Foundation of Australia. 2006; Women and heart disease: Summary. Australian Institute of Health 
and Welfare. June 2010. Available at: http://www.aihw.gov.au/publications/index.cfm/title/11193 [Date accessed 
17 December 2010]; Health expenditure Australia 2006–07. Australian Institute for Health and Welfare, 2008. 
Canberra: AIHW.
Canada: Dai, S., Bancej, C., Bienek, A., et al. Tracking Heart Disease and Stroke in Canada. Public Health Agency of 
Canada. 2009; Decline of cardiovascular disease. The Heart and Stroke Foundation. 2010. Available at: http://www.
heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm#heartdisease [Date accessed 17 December 
2010]; Statistics Canada CANSIM Table 102-0529: Deaths, by cause, Chapter IX: Diseases of the circulatory system (I00 
to I99), age group and sex, Canada, annual (number), 2000 to 2006. May 2010; Heart Disease. CIHR. Available at: 
http://www.cihr-irsc.gc.ca/e/documents/heart_disease_mpkit_2005_e.pdf [Date accessed 17 December 2010]
UK: Allender, S., Peto, V., Scarborough, P., et al. Coronary heart disease statistics. British Heart Foundation: London, 
2008; Deaths by cause, sex and age, 2007, United Kingdom. Office for National Statistics, 2008; Health Survey for 
England 2006: CVD and risk factors adults, obesity and risk factors children. The NHS Information Centre. January 
2008; UK Health Research Analysis. UK Clinical Research Collaboration, 2006. Available at: http://www.ukcrc.org/
researchcoordination/healthresearchanalysis/ukanalysis/ [Date accessed 17 December 2010]
Table 1.1
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research, only some also attempt to identify fac�
tors associated with success or payback – however 
defined. In the next section we concentrate on the 
most relevant aspect for this study, the use of the 
Payback Framework and the use of quantitative 
measures of impact to help identify factors asso�
ciated with research payback. More detail on the 
remaining groups of previous work is provided in 
our earlier report �Marjanovic et al., 2009).
The Payback Framework
There is a variety of approaches in the literature 
to identifying the payback from research, rang�
nature and mechanisms of the impacts made by 
health research.
To provide an evidence base to help inform 
funders’ decisions we need studies that explore 
which features of research, and translation   
processes, deliver these benefits. It is important 
that such studies seek to improve the effectiveness 
of funding rather than simply making the case 
for increasing, or maintaining, research support. 
As John Marburger, the former science advisor to 
President �eorge �. Bush, put it in an editorial in 
Science: “A new �science of science policy’ is emerg� “A new �science of science policy’ is emerg�
ing … But [this] demands the attention of a spe�
cialist scholarly community. As more economists 
and social scientists turn to these issues, the effec�
tiveness of science policy will grow, and of science 
advocacy too” �Marburger, 2005).
Previous work relevant to this study can be split 
into two main groups: studies working back from 
breakthroughs to identify research, and studies 
working forwards from research to identify impact. 
The latter group divides into collections of studies 
using different conceptual models, of which the 
Payback Framework is one. A separate distinc�
tion is that while all studies explore the impact of 
Figure 1.2
The Payback Framework’s logic model of the research funding process
SOURCE: Hanney et al., 2004
Knowledge production
Research targeting and capacity building
Informing policy and product development
Health and health sector benefits
Broader economic benefits
Figure 1.1
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The Framework has also shown itself to be suit�
able, with slight modification, for use in a range of 
research contexts from basic biomedical research 
through health services research, including social 
science and research in the arts and humanities 
��ooding et al., 2004, 2005, 2006; Hanney et 
al., 2007; Levitt et al., 2010). 
Increasingly the Payback Framework has been 
supplemented by methods for quantifying the 
level of payback, to facilitate cross�case compari�
sons and to allow the identification of factors that 
are associated with high payback, and so might 
be predictive of it. Its five payback categories 
allow this quantification to be done in a way that 
acknowledges that different paybacks may be of 
interest to different stakeholders. Our study builds 
on and develops those methods of quantification.
These characteristics have contributed to the 
Framework’s widespread adoption outside the UK, 
including the CIHR Impact Assessment Frame�
work, the Netherlands, Ireland and Hong Kong 
�Oortwijn et al., 2008; Nason et al., 2008; Kwan 
et al., 2007). In Canada the Canadian Academy of 
Health Sciences panel on return on investment in 
health research based their recommendations for 
all users and supporters of health research on the 
Payback Framework �Panel on Return on Invest�
ment in Health Research, 2009).
�e discuss how we assembled our payback case 
studies in more detail in Chapter 2.
ing from individual case studies, through logic 
models, to econometric modelling �Hanney et al., 
2007; Boaz et al., 2009; UK Evaluation Forum, 
2006; Committee on Science Engineering and 
Public Policy et al., 1999). These methods vary in 
the range of paybacks they consider and the extent 
to which they attempt to understand how that 
payback arises. The Payback Framework takes a 
wide definition of research payback running from 
the generation of new knowledge in academic 
papers through to societal and economic benefits 
�Buxton and Hanney, 1996; Hanney et al., 2004). 
It categorises these paybacks into five payback cat�
egories �shown in Figure 1.1).
Alongside this it attempts to understand how 
these benefits arise through a standardised logic 
model of the research funding process �shown in 
Figure 1.2).
The Payback Framework has the advantage 
of covering a wide range of the paybacks from 
research, and allowing cross�case comparisons 
by providing a uniform classification of paybacks 
and narrative structure. �hen used to structure 
case studies, as for Project Retrosight, it allows 
deep exploration of the circumstances and context 
of the research, from a variety of sources, as 
well as nuanced treatment of issues such as the 
contribution of research to particular paybacks 
�Croxon et al., 2001; UK Evaluation Forum, 
2006). This chapter provides an overview of our approach, 
alongside some of the checks we carried out to 
ensure the robustness of our data. We first discuss 
how we selected our methods, and in particular 
the Payback Framework as our approach; how 
we identified the subject area and countries to 
examine; and how we selected the funding period 
to focus on. We then step through the stages of 
our approach: identifying lists of research grants; 
estimating the payback of each grant through a 
survey of principal investigators (PIs); selecting a 
stratified random sample of grants; carrying out 
the case studies; quantifying the payback in each 
case; deriving impact categories for our analysis; 
and finally identifying common factors associ-
ated with payback. Our approach is presented dia-
grammatically in Figure 2.1. For more detail on 
the methods please see the accompanying Meth-
odology Report (Pollitt et al., 2011a).
Selecting our methods
The case study approach, combined with a robust 
sampling framework and a method for quantify-
ing our qualitative data, provided us with a way 
to understand the quantity and diversity of pay-
backs from the research and the context that led to 
them. We built up a detailed picture of each grant, 
how the research progressed and how it developed 
– a case study approach has often been used to 
address questions of research translation (Boaz 
et al., 2009). The case studies subsequently pro-
vided us with a rich source of material to examine 
for factors associated with payback. By using case 
studies, we effectively emphasised depth of under-
standing about a small sample of grants. In con-
trast we could have used surveys, or other meth-
ods, to collect a smaller set of information about 
more cases, i.e. we could have emphasised breadth. 
We chose to focus on depth because we wanted to 
understand the potentially subtle or unanticipated 
contextual factors that affected translation.
We selected the Payback Model in particu-
lar based on previous work where we surveyed 
the available evaluation frameworks (Brutscher 
et al., 2008). As noted in Chapter 1, in the Pay-
back Framework section, this choice has also been 
endorsed by the widespread adoption of the Pay-
back Model both in the UK and internationally.
Identifying a subject area, 
countries and funders
These processes effectively happened in parallel. 
We were keen to focus on an area of research, such 
as cardiovascular and stroke, that has large health 
benefits and potential impact (as outlined in the 
Introduction). Fortuitously, there was sufficient 
interest among funders in this area to support a 
study and it proved possible to build a consor-
tium of interested parties. Our country selection 
was driven largely by the availability of funders 
interested in supporting the project – but had the 
advantage of including research systems of com-
parable size, all working in the same language. It 
is also worth noting that the cardiovascular and 
stroke area has also been the subject of previ-
ous studies in the science of science (Comroe & 
Dripps, 1976; HERG et al., 2008).
Identifying a funding period
We chose grants as our unit of analysis because we 
wanted to be able to link payback to funding and 
also because available grant lists provided a popu-
lation from which to sample our case studies. We 
opted to focus on project grants/grants-in-aid to 
restrict the variety of funding in our sample.
We also had to decide how old the grants we 
studied should be, and selected an age range of 
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17–20 years, that is, grants with first-year fund-
ing awarded between 1989 and 1993. We did 
this to balance the need for reliable information 
against the need to allow enough time for research 
paybacks to develop. We also bore in mind stud-
ies examining the time lag between research and 
payback, which suggest that timescales of 15–20 
years are the norm (Di Masi et al., 1991; Grant et 
al., 2000; Balas and Boren, 2000; Contopoulos- 
Ionnadis, 2008; HERG et al., 2008).
Identifying all the grants and 
associated PIs
We combined grants awarded between 1989 
and 1993 by all members of the consortium: the 
National Heart Foundation of Australia; the Heart 
and Stroke Foundation of Canada; the Canadian 
Institutes of Health Research; the British Heart 
Foundation; and the UK Stroke Association. This 
gave us a list of 1347 grants.
Estimating payback of grants by 
questionnaire to PIs
To ensure robust identification of factors asso-
ciated with payback we needed to include case 
studies with a range of payback levels. We used 
a web-based survey that asked PIs a series of brief 
questions about impacts arising from their grants, 
from the number of papers published to effects on 
patient or public health. From their answers we 
made an initial estimate of payback for each grant. 
We also asked PIs to classify their grants as basic 
biomedical or clinical research, according to a 
standard definition we provided (see Figure 2.2).
We approached PIs by email, having obtained 
their address either directly from funder records 
Figure 2.1
A diagrammatic summary of the project methods
Research  Definition
Basic biomedical   Focuses on normal or 
abnormal function at the 
molecular, cellular, organ or 
whole body level
Clinical    Focuses on patients, on better 
diagnostics or treatments, and 
on increasing quality of life 
Figure 2.2
Definition of research type
Identifying factors that might explain 
variations in payback
Identiﬁed factors common to case studies with 
high academic or wider impact not shared with 
case studies with low impact using qualitative 
analysis of detailed case studies
Selecting our methods
Chose large-scale case study methods to 
allow for generalisation and provide depth 
of understanding to allow us to identify 
factors associated with payback
Identifying a subject area, countries 
and funders
Selected cardiovascular and stroke; Australia, 
Canada and UK for pragmatic and 
methodological reasons
Identifying a funding period
1989–1993 selected to balance need for 
reliable information against allowing enough 
time for research impacts to develop
Estimating payback of grants by 
questionnaire to PIs
Emailed PIs of the grants with online 
questionnaire to estimate the impact of the work 
on the grants
Selecting a stratiﬁed random sample
for case studies
stratiﬁed by: • Australia, Canada, UK
• Basic biomedical and clinical research
• High and low impact [•   Grant size]
Carrying out the case studies
Conducted 29 case studies where PIs agreed 
to take part in study. Used Payback Framework 
to structure case study data collection and 
write up
Quantifying payback from each case  
study
A rating panel who reviewed summaries of the 
peer-reviewed, detailed case studies 
Deriving impact categories
Examined payback ratings for correlations and 
combined them to produce two measures of 
impact. Divided case studies into groups 
based on these measures
Identifying all the grants and 
associated PIs
Used funder databases to identify the PIs for all 
grants in subject area from funders between 
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stratified our sample by the key characteristics we 
wished to analyse and then carried out a random 
case selection.
Key characteristics
We stratified the case studies by the following 
characteristics: basic biomedical versus clinical 
research, estimated payback, country of research 
and grant size. 
Type of research (basic biomedical vs clinical) 
– the relative merits of these two types of research is 
a perennial question for research funders.
Country of research – the project gave us 
an opportunity to examine whether the role of 
national context plays a significant role in research 
payback.
Payback of research – we wanted to ensure 
we had a balance of levels of payback in the case 
studies that would provide us with a solid basis 
to identify factors associated with impact. Such a 
sample would allow us to look for factors shared 
between higher-payback case studies, but not with 
lower-impact case studies. If we had used a purely 
random selection we could easily have ended up 
without this balance of payback levels. We saw 
this as a key methodological development as most 
research evaluation looks at high-impact research 
without a low-impact comparison.
Grant size – to allow us to explore the relative 
merits of grants of different sizes. However, in later 
(Canada and Australia) or through Google and 
Web of Science (Thomson Reuters) searches (UK). 
For pragmatic reasons in the UK we focused our 
efforts to locate email addresses on research-
ers who had published in the period 2004–6, as 
determined through searches of Web of Science.
We worked hard to minimise the biases in our 
sample; however, some will remain. The extent 
of these is hard to quantify; but our list of can-
didate case studies contained researchers with a 
wide distribution of academic age (Figure 2.3) and 
our case studies contain PIs at a range of career 
stages, from pre-PhD through post-doc to head of 
department.
Selecting a stratified random 
sample for case studies
We selected our case studies randomly after strati-
fying the grants according to the characteristics of 
research type (basic biomedical or clinical), esti-
mated payback (higher or lower) and country. 
The challenge with case study research is pro-
ducing findings that are transferable. This arises 
because case studies are carried out in small num-
bers (so may not be representative of the full range 
of possible case studies) and they are often selected 
purposively. In order to increase the likelihood 
that our findings would be transferable, we car-
ried out a relatively large number of case studies, 
Figure 2.3
A histogram showing the total number of years the PIs responding to our survey had spent in 
research by 2007
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ies had been started by the time the error was cor-
rected they were kept in the sample. This had a 
small effect on the distribution of cases across the 
matrix. Six PIs declined to participate in the study; 
in one other case, initial scoping following the PI’s 
agreement to take part revealed that the grant did 
not meet our inclusion criteria. In one instance the 
case study research was initiated, and although 
three interviews were completed, insufficient evi-
dence was available to allow compilation of a full 
case study report. This case was thus excluded 
from the sample. Finally, in one case the PI had 
moved to Japan and hence a face-to-face interview 
was not feasible. The net effect of these changes 
was to produce a study with 29 case studies, rather 
than 28 as originally intended, distributed across 
the selection matrix as shown in Figure 2.5.
Carrying out the case studies
We used the Payback Framework (see Chapter 1) 
to structure our case studies and drew on a vari-
ety of data sources. In each case we carried out 
a face-to-face interview with the PI, which was 
supplemented by other face-to-face and telephone 
interviews that may have included other members 
of the research team, their colleagues, collabo-
rators and competitors, practitioners, or policy 
makers who used their work. Where available, we 
reviewed funder documents such as applications 
and end-of-grant reports (these records were some-
times provided by the PI if they were not available 
from the funder). We also reviewed PIs’ publica-
tions from the grant period, and carried out a bib-
liometric analysis of publications attributed to the 
grant. Each case study is around 20 pages long and 
all are published in full in the accompanying Case 
Study Report (Pollitt et al., 2011b).
There was a separate team of case study research-
ers in each country. To improve consistency across 
the case study teams we held three international 
workshops, provided templates for interview 
schedules and write-ups, and two members of the 
UK team reviewed all initial drafts. To ensure his-
torical accuracy the case studies were cleared by 
the PIs and underwent external peer review. We 
attempted to have each case study reviewed by two 
experts in the field of the case study’s research – one 
from the same country as the case study and one 
from a different country. In the end 24 case stud-
ies were double- (or in two cases triple-) reviewed, 
analysis this proved problematic as the range of 
sizes was relatively small, differed between coun-
tries and was not always available for this retro-
spective sample in funders’ records. For these rea-
sons we have not attempted any analysis based on 
this stratification characteristic.
We carried out the stratified random selec-
tion by populating the selection matrix shown in 
Figure 2.4 for each country and then randomly 
selecting a case study from each cell.
There were three amendments to this process: 
as Canadian team members were able to perform 
additional case studies, we selected more case stud-
ies in Canada; we selected researchers to balance 
the gender ratio seen in our survey; and the Aus-
tralian and Canadian team members felt it was 
important to have a geographical spread of case 
studies to mirror the distribution of their funding 
by region at that time (in effect we stratified for 
gender and, in Canada and Australia, for location; 
but did not analyse using these variables). 
Two further factors slightly affected the sam-
pling: an initial classification error and refusal 
to participate. An initial error in data extraction 
from the survey led to the misclassification of 
some grants, but because some of these case stud-
Figure 2.4
Selection matrix
Clinical Basic
High
impact
Low 
impact
Quis nostr ud exercitation ullamco laboris nisi  
ut aliquip ex ea commodo consequat
Duis aute ir ure dolor in reprehenderit in 
voluptate velit
Esse cillum dolore eu fugiat nulla pariatur
Excepteur sint occaecat cupidatat non 
proident
Sunt in culpa qui of ﬁcia deser unt mollit anim  
id 
est laboru m
Duis aute ir ure dolor in reprehenderit in 
lpa qui of ﬁcia deser unt mollit anim id 
est 
Duis aute ir ure dolor in reprehenderit in  
voluptate
Esse cillum dolore eu fugiat nulla 
pariatur
Consectetur adipisicing elit
Sed do eiusmod tempor incididunt ut 
labore et dolore magna aliqua
nisi ut aliquip ex ea commodo consequat
Esse cillum dolore eu fugiat nulla 
pariatur
Excepteur sint occaecat cupidatat non 
proi
Duis aute ir ure dolor in reprehenderit in  
voluptate velit
Large 
grant
Lorem ipsum dolor sit amet
Consectetur adipisicing elit
Sed do eiusmod tempor incididunt ut labore et 
dolore magna aliqua
Ut enim ad minim veniam
Quis nostr ud exercitation ullamco laboris nisi 
ut 
aliquip ex ea commodo consequat
magna aliqua
Ut enim ad minim veniam
Quis nostr ud exercitation ullamco laboris nisi 
ut aliquip ex ea commodo consequat
Excepteur sint occaecat cupidatat non 
proident
Sunt in culpa qui of ﬁcia deser unt mollit 
anim id est 
Duis aute ir ure dolor in reprehenderit in  
voluptate
Esse cillum dolore eu fugiat nulla 
pariatur
Consectetur adipisicing elit
Quis nostru d exercitation ullamco 
laboris nisi ut 
aliquip ex ea commodo consequat
Esse cillum dolore eu fugiat nulla 
pariatur
Excepteur sint occaecat cupidatat non
Small 
grant
Consectetur adipisicing elit
Sed do eiusmod tempor incididunt ut labore et 
dolore magna aliqua
Excepteur sint occaecat cupidatat non proident
Sunt in culpa qui of ﬁcia deser unt mollit anim 
id est laboru m
Duis aute ir ure dolor in reprehenderit in 
voluptate velit
Esse cillum dolore eu fugiat nulla pariatur
Consectetur adipisicing elit
Sed do eiusmod tempor incididunt ut labore et
Lorem ipsum dolor sit amet
Quis nostru d exercitation ullamco 
laboris nisi ut aliquip ex ea commodo 
consequat
Duis aute ir ure dolor in reprehenderit in  
voluptate
Esse cillum dolore eu fugiat nulla 
pariatur
anim id est
Duis aute ir ure dolor in reprehenderit in  
voluptate
Consectetur adipisicing elit
Quis nostru d exercitation ullamco 
laboris
Large 
grant
Quis nostr ud exercitation ullamco laboris nisi 
ut 
aliquip ex ea commodo consequat
Esse cillum dolore eu fugiat nulla pariatur
Excepteur sint occaecat cupidatat non proident
Sunt in culpa qui of ﬁcia deser unt mollit anim 
id est laboru m
Duis aute ir ure dolor in reprehenderit in 
voluptate velit
Sed do eiusmod tempor incididunt ut labore et 
dolore magna aliqua
Ut enim ad minim veniam
Lorem ipsum dolor sit amet
Consectetur adipisicing elit
Sed do eiusmod tempor incididunt ut 
labore et 
dolore magna aliqua
Duis aute ir ure dolor in reprehenderit in  
voluptate
Esse cillum dolore eu fugiat nulla 
pariatur
Duis aute ir ure dolor in reprehenderit in  
voluptate
Esse cillum dolore eu fugiat nulla 
pariatur
Consectetur adipisicing elit
Small 
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and 5 cases were single-reviewed. For 23 of the 29 
case studies one or more reviewers reported that 
the overall assessment of impact as described in 
the case study was accurate. In six case studies, 
one or more reviewers suggested slight overstate-
ment of impact, in three cases significant over-
statement, and in two cases slight understatement. 
The distribution of reviewers’ comments is shown 
in more detail in Table 2.1.
Quantifying payback from each 
case study
We now had a set of 29 detailed case studies of 
research grants, and we wanted to use them to 
identify factors associated with payback. To do 
this we needed to determine which of our case 
studies had high payback and which low, so we 
could look for factors shared by the high payback 
cases and not shared with the others. We asked a 
panel of evaluators to rate each case study in each 
of the five payback categories – knowledge pro-
duction, research targeting and capacity building, 
informing policy or product development, health 
and health sector benefit, and broader economic 
Figure 2.5
Final case study matrix: completed case studies are shown as filled circles, refusals and exclusions as 
open circles
Reviewer 
assessment
Australia Canada UK
Significant 
understatement
Slight 
understatement
Accurate
Slight 
overstatement
Significant 
overstatement
Accuracy unclear to 
reviewer
 
0
 
2
10
 
1
 
3
 
3
 
0
 
0
15
 
3
 
1
 
4
 
0
 
0
15
 
2
 
0
 
0
Case studies with 1 
reviewer
Case studies with 2 
reviewers
Case studies with 3 
reviewers
Total case studies
 
1
 
6
 
1
8
 
3
 
8
 
1
12
 
1
 
7
 
1
9
Total reviewers 16 22 18
Figures represent the number of reviews in which each 
assessment of the overall accuracy of a case study was 
made. Some reviewers made more than one comment 
(for example, on different aspects of the case study) 
and so are included more than once. Additionally, some 
reviewers did not provide an overall assessment and so 
are not included in the table.
Table 2.1
Reviewer comments
Clinical Basic
High 
impact
Low 
impact
Large 
grant
Small 
grant
Large 
grant
Small 
grant
Canada   UK  Australia12    Project Retrosight
brought them together for a two-day workshop in 
which we discussed the ratings over which there 
was most disagreement, and allowed the panel to 
rate the case studies a second time. The aim of the 
workshop was to reduce differences in understand-
ing, for example, about the most appropriate clas-
sification of paybacks, but to preserve differences 
of opinion about the relative value of paybacks.
To give us confidence in the rating process we 
carried out a number of tests, reported in more 
detail in the Methodology Report. In summary, all 
members of the panel showed similar rating behav-
iour: they all used the full scale as directed, had 
median rates within one point of each other and 
their rating behaviour was not skewed. Agreement 
increased in the post-workshop ratings, although 
median rates changed only slightly: 79% of median 
ratings remained the same, 18% changed by 1, and 
2% changed by 2 or 3. There was enough agree-
ment in the median ratings to distinguish high-, 
medium- and low-impact groups, with around one 
third of case studies in each. 
Deriving impact categories
Once we had quantified the payback in each cat-
egory from each case study, we examined the 
median ratings to look for patterns. We were con-
cerned that identifying factors associated with 
high impact in all five payback categories would 
be unmanageable and so, if possible, we wanted 
to reduce the number of payback measures. We 
found that grouping the first two and the last three 
payback categories allowed us to produce two 
mutually exclusive groupings that also grouped 
the payback categories with the highest correla-
tion (see Table 2.2). From this we produced two 
impact categories: academic impact – encompass-
ing knowledge production, research targeting and 
capacity building; and wider impact – encompass-
ing informing policy and product development, 
health and health sector benefit and broader eco-
nomic benefit (Figure 2.6).
Identifying factors that might 
explain variations in payback 
To identify factors associated with impact we 
used our two impact measures – academic and 
wider – separately. For both measures we sorted 
case studies in order from high to low and then 
benefit.16 In this section we describe how we quan-
tified the payback for each case study.
First we recruited a panel of nine evaluators 
to rate our case studies. The panel was made up 
of both researchers familiar with the project 
and others new to it, who were invited to pro-
vide a degree of external validation. It included 
a case study researcher and an external expert 
on biomedical research funding from each proj-
ect country, as well as one expert from a country 
not included in the project to provide an entirely 
independent perspective. The full membership of 
the rating panel is detailed in the accompanying 
Methodology Report (Pollitt et al., 2011a).
We provided raters with printed tables sum-
marising the case study narratives and payback, 
the bibliometric analysis, an impact array of the 
paybacks and the peer reviewers’ comments. We 
also supplied the full case studies and peer review 
comments in electronic form. We did not provide 
the panel with information on the PIs’ initial pay-
back estimates, as we wanted to produce an inde-
pendent quantification of payback based on our 
case studies.
We asked the panel to provide a relative rating 
of the payback from each case study in each pay-
back category – that is, five ratings per study. Each 
rating was on a scale of 0–9 where 0 was no pay-
back, 1 was the least payback in the set of case 
studies and 9 the most. Raters had to give one 
case a 1 and one case a 9, thus ensuring full use 
of the scale and therefore variability, but could 
give more than one case study the same rating: ties 
were allowed. We chose to use a relative scale for 
the following reasons: because of the difficulty of 
developing absolute impact scales; because we felt 
ranking all 29 case studies in order would be too 
difficult; and because using an ordinal scale made 
it easy to present agreement measures (for more 
details see the Methodology Report). As we have a   
stratified random selection of case studies the range 
of payback in these should approximate the range of  
payback from the full set of project grants.
The panel provided an initial set of ratings that 
showed a considerable level of agreement. We then 
16  We also rated the case studies on overall impact and value for 
money – these are discussed in more detail in the Methodology 
Report (Pollitt et al., 2011a), along with the reasons why we have 
not used them for analysis.Methods    13
high- and low-impact cases, rather than two over-
lapping groups (see Figure 2.7 for a diagrammatic 
representation of the process).
This sorting process initially gave us six groups 
of case studies: three relating to academic impact 
(high, mid and low), and three relating to wider 
impact (high, mid and low). In line with the lack 
of correlation found between academic and wider 
impact, the overlap between, for example, the two 
high-impact groups was not extensive (four case 
studies had both high academic and high wider 
impact).
To allow us to analyse each type of research – basic 
biomedical and clinical research – separately we 
took each type in turn and split those case stud-
ies into high, mid and low impact groups, as we 
had done with the complete set of case studies. 
On this occasion case studies were only ranked 
with case studies of the same type ie clinical case 
studies were only ranked with clinical case stud-
ies. Because of this the split points for high, mid 
and low groups were not always in the same place 
when all the case studies were considered together. 
This is illustrated in Figure 2.7.
To identify factors associated with impact we 
examined the full case studies, coding the presence 
or absence of factors using NVivo, a qualitative 
analysis software package17. We identified an ini-
tial list of factors from our background knowledge 
and through discussions at the project and rating 
workshops. We also added factors that seemed of 
interest when we reviewed the case studies.
17  We used NVivo 8, which has now been updated; QSR   
International.  NVivo software. http://www.qsrinternational.com/ 
products_nvivo.aspx [Accessed 16 December 2010]
divided them into three groups – high-, mid- 
and low-impact. Further detail on the process by 
which these groups were defined is provided in the 
accompanying Methodology Report (Pollitt et al., 
2011a). High- and low-impact groups could then 
be compared to a series of binary variables repre-
senting the presence or absence of each factor in 
each case study. Grouping case studies in this way 
and focusing on the two “extreme” subgroups did 
mean that we did not use all of the data at the 
initial stage of analysis, but this is a well-estab-
lished technique in scale development, and divi-
sion into three groups to conduct such analysis is 
in line with the standard method for computing 
classical discrimination indices (e.g. Crocker and 
Algina, 1986). As there was some uncertainty in 
our impact measures we used a mid-impact group 
to ensure that we had a clear distinction between 
Table 2.2
The correlations between ratings in each payback category
Knowledge 
production
Research 
targeting & 
capacity building
Informing policy 
& product 
development
Health &  
health sector 
benefits
Broader  
economic 
benefits
KP 1 0.424 0.112 0.106 0.036
RTCB 0.424 1 0.286 0.334 0.187
IPPD 0.112 0.286 1 0.748 0.441
HHSB 0.106 0.334 0.748 1 0.52
BEB 0.036 0.187 0.441 0.52 1
Coefficients in bold italic are significant at a 0.01 level
Spearman’s rho and 2-tailed significance; n = 261 (29 projects x 9 raters)
Figure 2.6
Payback categories and impact groupings
Payback categories
Knowledge production
Research targeting and 
capacity building
Informing policy and
product development
Health and health sector
beneﬁts
Broader economic beneﬁts
Wider
impacts
Academic
impacts
Impact groupings14    Project Retrosight
Figure 2.7
A diagrammatic overview of the analysis process to identify factors associated with impact
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To prepare our groups of case studies for analysis to identify factors associated with academic impact: we ﬁrst 
sorted all the case studies (basic and clinical together) in ascending order of academic impact (1) then split 
them into three roughly equal groups: high-impact, mid-impact and low-impact (2). See Methodology Report 
for exact details of splitting methodology.
To look in more detail at the characteristics of basic biomedical research we took only the basic case studies (3) 
(clinical case studies shown faded to grey) and split them into high-, mid- and low- impact groups (4) . When we 
were considering only the basic case studies the low/mid split point fell in a slightly different place. This means 
two basic case studies are mid-impact when considering all the case studies but low-impact when considered 
with just the basic case studies (5).  We then carried out a similar process for the clinical case studies by 
themselves (6&7) (basic case studies shown faded to grey). On this occasion both split points differed.
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6
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parison group changes when considering just basic 
biomedical or clinical case studies rather than all 
case studies, the split points between groups is not 
always the same. In other words the group of high- 
impact case studies for “all case studies” is not the 
combination of the high-impact basic biomedical 
and clinical case studies. Additionally, we used 
the Fisher Exact test to determine the likelihood 
of non-random associations between the variables. 
We selected the Fisher Exact test as it relies on 
fewer assumptions (normal distribution assump-
tion is not needed) and is particularly useful for 
testing relationships in small samples (Cochran, 
1954). Because of the small sample size, we did 
not use more complex methods such as an ordered 
logistic regression model and, in particular, we did 
not attempt to adjust for covariates. In each case, 
we show the data for each of the six panels, and 
as an indication of importance, shade the panels 
where the Fisher Exact p value is lower than or 
equal to 0.2 (to one significant figure). Because of 
the nature of our sample, we do not interpret the 
results in the standard way, as indicating a “sig-
nificant” association, but instead as providing us 
with a relative indication of the likely robustness 
We tackled the coding process by working ini-
tially with half of the case studies. Two members 
of the research team, working independently, took 
the high-impact cases and looked for common 
factors. They then compared notes to identify fac-
tors both had observed. Two further members 
of the research team did the same for the low-
impact case studies. The research team then came 
together and all the factors were reviewed and 
clarified. We then addressed the cases that had not 
yet been examined, using the finalised list of fac-
tors, and revised the analysis of the initial cases in 
the light of the refined list. Finally, each factor was 
analysed quantitatively and qualitatively. To carry 
out the quantitative analysis, we looked at the bal-
ance of the factor’s occurrence across high, mid 
and low academic and wider impact case studies. 
Having grouped the case studies into low-, mid- 
and high-impact groups for both academic and 
wider impact, and examined those groups for all 
case studies, and basic biomedical and clinical case 
study groups separately, we present the results for 
each factor of interest graphically using a standard 
six-panel layout of graphs; an example is shown in 
Figure 2.8. As explained earlier, because the com-
Figure 2.8
Example of graphs for factor of interest
All Case Studies Basic Case Studies Clinical Case Studies
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of our associations. Because the randomisation in 
our sample is stratified we do not suggest that the 
figures are absolute measures or suggest that their 
exact value is interpreted – one reason for quoting 
them to only one significant figure. 
For the qualitative analysis, we assigned each 
factor to a coder who reviewed all the occurrences 
of each theme to ensure consistency of interpre-
tation. Resource limitations meant that we could 
not double-code cases, but by coding first by case 
study and then by factor we hope to have removed 
the majority of inconsistencies.
We presented our initial list of factors associated 
with impact at an Emerging Findings Workshop 
in London in April 2010, which was attended by   
collaboration members and a variety of policy makers 
and evaluators from cardiovascular and stroke 
research and wider health research, from the UK and 
overseas. The workshop highlighted a number of 
areas for further analysis and helped refine our think-
ing about the context of our work. Taking these sug-
gestions into account and drawing on the contextual 
knowledge of the research team, we developed our 
observations into policy implications.Project Retrosight was not without some struc-
tural, methodological and scope limitations; how-
ever, while those must be acknowledged, we feel 
that they are balanced by the study’s strengths.
Project Retrosight used more case studies than 
any other similar study we know of and selected 
them in a stratified random way designed to mini-
mise biases and subjectivity. The 29 cases were 
structured using a comprehensive conceptual 
framework that helped ensure consistency across 
the full set and allowed for robust comparisons to 
be made. Case study quality was assured through 
review of the case studies by both the PI of the 
research project that formed the subject of each 
case study and two external subject experts. All 
were asked to assess the accuracy of the case study 
narratives and the impacts claimed.
Furthermore, the whole project was reviewed 
by two reviewers from outside the project team. 
Our international approach to the project brought 
strength in allowing us to consider a wider range 
of research contexts and to develop robust observa-
tions that are relevant internationally, but despite 
our best endeavours there are indications that we 
did not manage to fully standardise the case stud-
ies across the three countries.
The attribution of impact to specific research 
grants is an issue central to research evaluation, 
and while it is impossible to definitively allocate 
every impact to an individual piece of funding, 
we addressed this issue in Project Retrosight by 
attempting to quantify whether the case studies 
differed in the scope of the funding considered. 
We found that this bore no relationship to impact. 
The accuracy of the classification of our case stud-
ies was a second potential source of bias and so we 
examined the robustness of our findings by test-
ing alternative definitions of our selection criteria. 
Finally, due to the challenges associated with esti-
mating the impact of negative or null findings, we 
also tested our observations on the full set of case 
studies with and without these grants included.
Number and selection of case 
studies
In case study research the challenge is to select a 
sample from which transferable findings can be 
developed, as the number of case studies available 
is limited. If the sample is small and selected at 
random, the results may be partial or incomplete. 
However, if the selection is too deliberate, there is 
a risk of biasing the findings of the study or limit-
ing the conclusions that can be drawn from the 
data. It follows that there are two ways to address 
this challenge: using a larger sample and careful 
selection of cases. We used both approaches for 
Project Retrosight.
The number of cases used in Project Retrosight 
was substantially larger than in many previous 
projects of a similar nature, for example: 
•	 sixteen cases in a study for the Arthritis 
Research Campaign (Wooding et al., 2005);
•	 eight cases in a study with the Irish Health 
Research Board (Nason et al., 2008);
•	 ten cases in a study conducted at the London 
School of Hygiene and Tropical Medicine 
(Kuruvilla et al., 2007).
We selected using a stratified random sample that 
retained a random element while ensuring balance 
across our three key characteristics: type of research, 
size of grant, and an estimate of impact level based 
on initial information from our PI survey.
We aimed to include examples of both high 
and low impact – a key strength of the study 
– by stratifying on the PIs’ initial estimates of   
payback. In doing this, we have been able to dem-
onstrate not only the presence of certain character-
istics in high-impact research, but also their absence 
Chapter 3   Strengths and limitations of the 
methodology18    Project Retrosight
Chris Henshall (Brunel University and the Uni-
versity of York).
International approach
As far as we are aware, Project Retrosight is the 
first study to assess the impact of research across 
a number of countries using such a coordinated 
approach. This raised two concerns – we needed a 
consistent approach to case study authorship and 
our sample selection needed a similar balance of 
estimated high- and low-impact case studies for 
each country. 
One of the aims Project Retrosight initially set 
out to explore was the extent to which factors asso-
ciated with impact were consistent across countries. 
How likely was it that findings from one country 
could be generalised to others? The study found 
few differences between countries in the distribu-
tion of factors associated with impact. More ambi-
tiously, we hoped to see if one particular country’s 
methods were associated with impact. To do this 
we had to ensure the process of case study research 
in each country did not affect the apparent impact 
of the case. Unfortunately, although we expended 
considerable effort to ensure consistency across 
country teams, the design of the study made it 
impossible to show we had achieved this, and there 
are some indications that we had not. 
Case study authorship
The concern for consistency in authorship was par-
ticularly acute because during case study research 
on payback a series of judgements had to be made 
about how to consider the scope of the work under 
examination, to ensure comprehensive description 
of impacts without exaggeration and to estimate 
the level of contribution made by the impacts 
identified.
To minimise the effect of these differences we 
had three international project meetings, regular 
conference calls and tuition to ensure the entire 
project team was involved in making such judge-
ments. We also provided case study templates, 
interview protocols and project plans. The devel-
opment of the individual case studies was an itera-
tive process, which involved review of the draft 
case studies by the RAND/HERG team.
We then submitted all the cases to external 
peer review, and asked the reviewers how accu-
rately the case study reported the impact of the 
in low-impact research. We do not know of any 
other studies that have taken such an approach.
Conceptual framework
The use of a consistent and comprehensive frame-
work to structure case study material helped   
ensure that a range of case studies producing a 
diverse array of impacts could be reliably compared. 
The Payback Framework has been extensively used 
to measure research impact in a variety of contexts, 
both by the research team and other groups, and 
its use throughout the data collection, analysis and 
reporting of Project Retrosight has supported the 
study’s clear focus and consistent structure.
The process of applying the Payback Frame-
work and associated methods of data collection 
is also well established, providing a robust base 
from which to expand the scope of the project (for 
example, to low-impact case studies) and build 
innovative analysis. The Framework also sup-
ported the quantification of qualitative case study 
material through the rating process. This quantifi-
cation allowed a more thorough and robust com-
parison of factors associated with impact than has 
previously been attempted.
External peer review
To ensure the accuracy of the case studies and to 
highlight any areas of concern, each case study 
was reviewed by the PI involved. To address issues 
of viewpoint, we identified two subject experts 
who also reviewed each case – one from the same 
country as the PI and one from a different coun-
try. This external review aimed to validate the case 
studies in the wider context of the cardiovascular 
and stroke research field, with reviewers focusing 
on the accuracy of the impacts attributed, the sci-
ence described and the degree to which the PIs 
were reported to be leaders in their field. This is 
described in Table 2.1 on page 11 in more detail. 
We included a summary of the peer review com-
ments with each published case study, and our 
rating panel was given the full set of comments. 
Ideally, we would have liked to integrate the com-
ments into the case studies, but the project time-
lines meant this was not feasible.
The project as a whole was subject to peer review 
through RAND’s Quality Assurance system. 
Reviewers were Tom Ling (RAND Europe) and Strengths and limitations of the methodology    19
bution of publications (in particular) to the grant, 
while the independent peer review process pro-
vided some degree of validation for the range of 
impacts claimed.
There are two dimensions where assessments of 
attribution may be inaccurate – there may be inputs 
that we did not consider as part of the grant, and 
there may be payback or impacts to which other 
grants contributed. Despite our attempts to focus 
solely on one grant, there is a range of additional 
inputs to the research evaluated in the case studies. 
The key point to consider when addressing this is 
whether any of the benefits identified would have 
arisen without the specific grant in question. For 
this reason we analysed the scope of the work each 
case study encompassed – our concern was that 
case studies might report more payback because 
they extended beyond the case study grant. In 
essence, grants with more overlap would do better 
as they were getting the “credit” for the impact of 
a larger amount of research. To test whether this 
was so we classified the case studies according to 
the extent of overlap with other research done by 
the researcher before and concurrently with the 
case study grant (for details of this process see the 
accompanying Methodology Report, Pollitt et al., 
2011a). We saw no relationship between the extent 
of overlap of the case studies and their academic or 
wider impact. This reassured us that scope was not 
a confounding factor.
Classification of the case studies
We attempted to stratify our sample of case stud-
ies across four dimensions – country of research, 
initial estimate of impact, type of research (basic 
biomedical or clinical), and size of grant. The first 
of these was easy to establish as all our funders 
provided funding only in their own country. The 
second was intended to ensure we included lower 
payback cases in our study sample and appears 
to have worked as planned. The classification by 
type of research was broadly successful, but is of 
such importance that we consider it in more detail 
below and treat it as a confounder. Finally, dis-
tinction according to grant size was abandoned 
because the range of sizes in our sample was small, 
differed between countries and was sometimes 
impossible to gauge from funder records. (For 
more details, see the accompanying Methodology 
Report, Pollitt et al., 2011a).
grant. The majority of these comments suggested 
our case studies were accurate; however, the bal-
ance of comments across the countries was mark-
edly uneven (see Table 2.1 in Chapter 2). Ideally we 
would have been able to separate the effects of case 
study authorship and case study country to deter-
mine whether we had genuine differences between 
the countries; unfortunately, as the country and 
research teams were exactly aligned, this was not 
possible. This means we are unwilling to make con-
clusions based on differences between countries.
To ensure our more general observations were 
robust, we treated country as a confounder. To do 
this, we examined the distribution of each iden-
tified factor across countries. For two factors we 
found a distribution across countries that should 
be considered a caveat in interpreting our obser-
vations. We discuss this in more detail when we 
present each in Chapter 4.
Sample selection
To allow us sensibly to compare the average ratings 
by payback category across countries we needed to 
have a similar balance of case studies with estimated 
high and low impact in each country. Unfortu-
nately, due to problems with the selection process 
and some refusals to participate, we did not achieve 
this. Australia in particular had a larger number of 
estimated high-impact case studies in the basic 
biomedical category than other countries.
As the differences between countries were rel-
atively small, in our view they could have been 
accounted for by country, sample selection or 
authorship differences. This contributes to our 
reluctance to draw observations based on the dif-
ferences between countries.
Attribution
The attribution of payback or impact to specific 
research grants or funders is an issue central to 
research evaluation. This issue was explored in 
some depth at a 1999 international workshop on 
research evaluation (Buxton et al., 1999; Croxson 
et al., 2001), where it was concluded that there are 
many complications in identifying the impact of 
specific funding.
In Project Retrosight, we attempted to assess 
the impact of 29 individual research grants. The 
Payback Framework and project protocols devel-
oped by the team provided guidance on the attri-20    Project Retrosight
definition of whether or not the research involved 
direct contact with patients. Two members of 
the research team applied these definitions. The 
results of the comparison (Figure 3.1) show a 
generally good agreement between the PIs’ defi-
nitions and the Frascati Manual, and even closer 
agreement with the “touches patients” definition. 
Because of the importance of this distinction to 
our analysis we treated it as a confounder and 
examined the effect of “flipping” the case studies 
with least agreement between definitions on our 
observations. We discuss where “flipping” might 
change our observations in the section on the rel-
evant association.
Estimating the impact of negative 
or null findings
We classified seven of our case studies as reporting 
negative or null findings. The concept of negative 
or null results has various definitions,19 but we use 
it to cover studies that fail to confirm or disprove a 
hypothesis, or disprove a hypothesis and preclude 
further work (for example, by demonstrating the 
19  See the editorial guidelines of Journal of Negative Results in Bio-
medicine and Journal of Negative Results (Ecology and Evolutionary 
Biology).
Turning to the basic biomedical or clinical clas-
sification; although this distinction is almost uni-
versally accepted in the field of health, the exact 
border between the two can be very hard to deter-
mine. There is always likely to be some research 
that does not sit easily in either category, or which 
incorporates elements of both. We found that each 
of our funders had a slightly different way of dis-
tinguishing between basic biomedical and clini-
cal research. Because of this we asked the PIs to 
classify their research according to the following 
hybrid of our funders’ definitions:
•	 basic biomedical – focuses on normal or abnor-
mal function at the molecular, cellular, organ 
or whole body level;
•	 clinical – focuses on patients, better diagnostics 
or treatments and increasing quality of life.
Because the basic biomedical/clinical distinction 
is not universally used, we wanted to test whether 
our observations would be robust against alterna-
tive definitions. We therefore tested the interna-
tionally recognised Frascati Manual classification 
published by the OECD18 and a more informal 
18  In order to test agreement with our basic biomedical/clinical 
definition we treated Frascati applied research as equivalent to clini-
cal and Frascati basic research as equivalent to basic biomedical.
Figure 3.1
A comparison of the alternative research type definitions as applied to the case studies
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The available literature suggests that nega-
tive or null findings are less likely to be published 
than positive findings, which suggests they will be 
associated with lower impact (Gould, 1993). It is 
likely that our methodology will underestimate 
the impact of such studies as it will be harder to 
identify and evaluate an impact that causes some-
thing not to happen – an area of research that is 
not pursued, saving money for more productive 
research – than an impact that causes something 
observable to happen. 
absence of a link between two systems). As we 
expected negative or null findings to be indepen-
dent of other factors that might influence impact, 
we were concerned that a coincidental association 
between negative or null findings and a second 
factor could lead us to make inaccurate observa-
tions. We therefore tested the distribution of case 
studies with each factor associated with impact 
before and after excluding case studies with nega-
tive or null findings. We discuss the results of this 
analysis for each association in Chapter 4.In this chapter we describe each of the key find-
ings or observations from our analysis and assess 
the nature of the evidence base for it in our study, 
and associated policy implications. We describe 
the findings in three subsections.
•	 A	large	and	diverse	range	of	research	impacts	
arose	from	the	29	case	studies:	the evidence 
for these findings comes directly from the 29 
studies of cardiovascular and stroke research 
grants. 
•	 The	patterns	and	extent	of	impacts	are	very	
variable:	the analysis for these findings is based 
on the rating of the 29 case studies described 
in the previous chapter, and thus allows a more 
structured analysis than on the basis simply of 
the “raw” case study data.
•	 Factors	 associated	 with	 impact: our find-
ings here are based on analysis of the relation-
ship between the case study ratings and factors 
that may be relevant to impact, identified as 
described in Chapter 2. 
A large and diverse range of 
impacts arise from the 29 case 
studies of cardiovascular and 
stroke research
We identified a large and diverse range of research 
impacts arising from the 29 case studies on car-
diovascular and stroke research. The Payback 
Framework classifies research impact into five 
categories.
As illustrated in Tables 4.1, 4.2 and 4.3, the 
impacts of these 29 research grants captured in 
each of the five payback categories are diverse and 
far-reaching.
These findings resonate with the diversity of 
payback identified in an earlier study of the impacts 
from arthritis research (Wooding et al., 2004). It is 
unlikely that the full extent of these impacts would 
have been identified without the structured case 
study approach employed in both studies. 
The nature of the distribution of broader eco-
nomic benefits (the fifth payback category) is dis-
cussed on page 27. But it is important to note here 
that the definition of broader economic benefits 
used in this study, and as described in the three 
country tables, relates to the commercial devel-
opment and uptake of products informed by the 
research findings; and the human capital approach, 
that is, considering the benefits from a healthy 
workforce in terms of the value of lost production 
avoided as a result of reductions in mortality and 
morbidity. We do not include in this category the 
value to the economy of the PhD training provided 
nor the intrinsic value of health benefits, although 
these too can be seen as economic benefits (HERG 
et al., 2008).
The patterns and extent of 
impacts are very variable
In addition to cataloguing the diversity of impact, 
it is also apparent that the pattern of impacts is 
very variable. We now describe three aspects of 
this variation.
There are variations between the 
impacts derived from basic biomedical 
and clinical research
As Figure 4.1 shows, there are differences in the 
impact of basic biomedical and clinical research. 
For the two academic impact categories – “knowl-
edge production” and “research targeting and 
capacity building” – all the case studies were rated 
at least 1 for impact (with raters having the option 
to rate 0 if there was no impact); however, the aver-
age rating was higher in basic biomedical research 
than in clinical research. 
Chapter 4   Findings, observations and policy 
implications24    Project Retrosight
Table 4.1
Selected impacts from eight projects funded by the National Heart Foundation of Australia 
Payback category  Total contribution and examples
Knowledge production:
peer-reviewed publications.
•	 All Australian projects (five initially estimated to be high impact, three 
initially estimated to be low impact) produced peer-reviewed publications.
•	 A project on immunoelectron microscopy of amine and peptide synapses on 
sympathetic preganglionic neurons resulted in 18 articles that have received 
a total of 780 citations.
Research targeting and capacity 
building: 
post-graduate research 
training; career development of 
PI and team; transfer of skills; 
informing future studies.
•	 All Australian projects (five initially estimated to be high impact, three 
initially estimated to be low impact) contributed to this category.
•	 A project on high density lipoprotein (HDL) led to a large number of 
collaborations for the PI and advanced the career of the post-doc; it also 
resulted in new research techniques, further research funding for the group 
and better targeting of other groups through increased understanding of 
HDL.
•	 A follow-up study of heart attack patients trained PhD students; expanded 
population data for future studies.
Informing policy and product 
development: 
informing a wide range of 
policies, including clinical 
guidelines; informing the 
development of therapeutic 
products, diagnostic tests, etc.
•	 All Australian projects (five initially estimated to be high impact, three 
initially estimated to be low impact) contributed to this category.
•	 A project that created animal models for myocardial dysfunction had 
contributed to the decision to create a transgenic facility at the research 
institute, which later informed the development of a commercial facility.
•	 Research on the secondary prevention of hypertension was cited in two 
clinical guidelines.
Health and health sector 
benefits: 
health gains from improved 
treatments and public 
health; more effective use of 
healthcare resources; increased 
health equity.
•	 All Australian projects (five initially estimated to be high impact, three 
initially estimated to be low impact) contributed to this category.
•	 A project studying the effects of angiotensin converting enzyme (ACE) 
inhibitors had provided part of the international literature used to justify 
their adoption in the treatment of LV hypertrophy, hypertension, cardiac 
disease, etc; there have been major health gains from the introduction of 
ACE inhibitors.
•	 A project studying the follow-up to heart attacks contributed to a major 
international project on health promotion, which in turn contributed to a 
decline in coronary heart disease in the Hunter region.
Broader economic benefits: 
benefits to the economy such as 
greater employment, exports, 
etc., as a result of commercial 
development informed by the 
research; contribution to a 
healthier workforce through a 
reduction in production lost by 
mortality and morbidity.
•	 Five of the eight Australian projects contributed to this category, of which 
four were initially estimated to be high impact, and one was initially 
estimated to be low impact.
•	 The commercial transgenic facility developed as a result of the animal models 
for myocardial dysfunction is now a multi-million-dollar business that exports 
80% of its services.
•	 A project on the effects of lean meat diets on plasma lipids and haemostatic 
function might have contributed to a larger body of work that, in turn, might 
have contributed to identifying the health benefits of lean meat and benefits 
for the meat industry (a higher value market for lean meat).
For the three wider impact categories the pattern 
was reversed. For the payback category “informing 
policy and product development” over one third 
(6 of 15) of the case studies on basic biomedical 
research were rated 0, compared to no clinical case 
studies. In the “health and health sector benefits” 
category, 8 of 15 basic biomedical case studies rated 
0 compared to 2 of 14 clinical projects. Finally, 11 
of 15 basic biomedical projects were rated 0 or more 
for “broader economic benefit” compared to 8 of 
14 clinical projects – although it should be noted 
that the case study rated highest in this category 
was a basic biomedical project. When the three ele-
ments of wider impact were combined, all clinical 
Figure 4.1
Mean impact rating by payback category and 
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Table 4.2
Selected impacts from 12 projects funded by the Heart and Stroke Foundation of Canada and the 
Canadian Institutes of Health Research
Payback category  Total contribution and examples
Knowledge production:
peer-reviewed publications.
•	 All Canadian projects (six initially estimated to be high impact, six initially 
estimated to be low impact) produced peer-reviewed publications.
•	 A project on the genetic and cellular determinants of increased growth of 
vascular smooth muscle in spontaneously hypertensive rats produced a series 
of journal articles. Sixteen articles produced 849 citations and included a 
paper in the highly prestigious Journal of Clinical Investigation. 
Research targeting and 
capacity building: 
post-graduate research 
training; career development 
of PI and team; transfer of 
skills; informing future studies.
•	 All Canadian projects (six initially estimated to be high impact, six initially 
estimated to be low impact) contributed to this category.
•	 A project on the effects of simulated stroke on developing astrocytes resulted 
in two PhDs; techniques were taught to students and visiting researchers. 
•	 A project on low-intensity warfarin and thrombosis resulted in one MSc, 
refinement of assays, and informed some major follow-on projects. 
Informing policy and product 
development: 
informing a wide range of 
policies, including clinical 
guidelines; informing the 
development of therapeutic 
products, diagnostic tests, etc.
•	 Eleven of the 12 Canadian projects contributed to this category, of which five 
were initially estimated to be high impact and six were initially estimated to 
be low impact.
•	 Guidelines recommend a treatment pathway for antiphospholipid antibodies 
(APLA) based on the original warfarin-based project (described above); work 
on the follow-on studies is cited in guidelines for warfarin therapy.
•	 A project on prolonged heart and lung allograft preservation was part of a 
much larger body of research referenced in guidelines and contributing to 
working with industry.
Health and health sector 
benefits: 
health gains from improved 
treatments and public 
health; more effective use of 
healthcare resources; increased 
health equity.
•	 Seven of the 12 Canadian projects contributed to this category, of which four 
were initially estimated to be high impact and three were initially estimated 
to be low impact.
•	 The treatment path for APLA patients is much improved, leading to some 
health gain. 
•	 A project on nimodipine binding in cerebral ischemia was part of a stream 
of work included in the Canadian Best Practice Recommendations for Stroke. 
This study, along with many others, has led to health gains and cost savings 
through the administration of tissue plasminogen activator.
Broader economic benefits: 
benefits to the economy 
such as greater employment, 
exports, etc., as a result of 
commercial development 
informed by the research; 
contribution to a healthier 
workforce through a reduction 
in production lost by mortality 
and morbidity.
•	 Two of the 12 Canadian projects contributed to this category, of which one 
was initially estimated to be high impact and one was initially estimated to be 
low impact.
•	 A project on cell–cell interactions in the disposition of natriuretic peptides 
in bovine chromaffin cells used a radioimmunoassay the PI had created 
previously. It helped lead to kits now sold by a commercial company.
•	 A project on coronary lesions and vasoactivity in salmon led on to a body of 
work that contributed to the literature showing farmed salmon are a safe 
source of human dietary omega-3 input, thus contributing to sustainable 
aquaculture. 
case studies had some wider impact (i.e., a rating of 
at least 1 in one of the three wider impact payback 
categories) compared to only 6 of 15 of the basic 
biomedical case studies.
These results suggest that basic biomedical 
research has a greater academic impact and clini-
cal research has a greater wider impact. This obser-
vation needs to be interpreted with care, given 
the time lags involved in realising payback in the 
wider impact categories. Although data on how 
long it takes to translate bodies of research from 
bench to bedside are relatively sparse, 17 years is 
commonly cited (Balas and Boren, 2000; Grant et 
al., 2000; HERG et al., 2008; Morris et al., forth-
coming). For Project Retrosight, the time between 
the research project period (1989–93) and the 
fieldwork for the case studies (2008–9) was 15–20 
years. In other words, a full or partial explanation 
for the difference found in the current study in 
wider impacts for basic biomedical and clinical 
research could be that clinical research is further 
downstream than basic biomedical research and 
thus has a greater opportunity to realise impacts 
in the timescales considered in this project. Both 
basic biomedical and clinical research produce a 
wide range of benefits, but within a time period 
of 15–20 years it is likely that basic biomedi-
cal research will produce more of the traditional   26    Project Retrosight
Table 4.3
Selected impacts from nine projects funded by the British Heart Foundation and the Stroke Association
Payback category  Total contribution and examples
Knowledge production:
peer-reviewed publications.
•	 All UK projects (four initially estimated to be high impact, five initially 
estimated to be low impact) produced peer-reviewed publications.
•	 A project on the role of coagulation and fibrinolysis in the pathogenesis of 
recurrent stroke led to a series of articles, seven of which have been cited 
393 times in total.
Research targeting and capacity 
building: 
post-graduate research training; 
career development of PI 
and team; transfer of skills; 
informing future studies.
•	 All UK projects (four initially estimated to be high impact, five initially 
estimated to be low impact) contributed to this category.
•	 The project (above) led to two PhDs, an MD and development of a patient 
cohort and control group that formed the basis of a stream of work. It 
helped the PI establish his research group.
•	 A project on lipoprotein production led to a PhD and new molecular biology 
equipment and techniques in the lab, which produced a significant change 
in research direction.
Informing policy and product 
development: 
informing a wide range of 
policies, including clinical 
guidelines; informing the 
development of therapeutic 
products, diagnostic tests, etc.
•	 Four of the nine UK projects contributed to this category, of which two were 
initially estimated to be high impact and two were initially estimated to be 
low impact.
•	 A project on stroke prevention in the elderly in primary care informed 
guidelines in a working group statement and protocols of local units in the 
health service.
•	 A project on the incidence, severity and recovery of language disorders 
following right-hemisphere stroke has been cited in the national guidelines, 
informed curriculum development of a speech therapy school and informed 
a patient leaflet. 
Health and health sector 
benefits:
health gains from improved 
treatments and public health; 
more effective use of healthcare 
resources; increased health 
equity.
•	 Four of the nine UK projects contributed to this category, of which two were 
initially estimated to be high impact and two were initially estimated to be 
low impact.
•	 A project analysing the results of the Heartstart Scotland initiative to 
introduce automated defibrillators into all Scotland’s ambulances is widely 
cited in guidelines and informed policy of ambulance services in Scotland 
and England. As a result it has made an important contribution to the 
increased survival rate following out-of-hospital cardiac arrest.
•	 A project on fibrillin deficiency in Marfan syndrome has contributed to 
international research that improved diagnostic tests and informs preventive 
management that has pushed the average age of death higher; also, health 
gain from reassuring family members who do not have the mutation.
Broader economic benefits: 
benefits to the economy such as 
greater employment, exports, 
etc., as a result of commercial 
development informed by the 
research; contribution to a 
healthier workforce through a 
reduction in production lost by 
mortality and morbidity.
•	 Three of the nine UK projects contributed to this category, of which two 
were initially estimated to be high impact and one was initially estimated to 
be low impact.
•	 The project on automated defibrillators has led to increased survival rates 
from cardiac arrest and it is possible that a few people have been able to 
return to work who might not otherwise have done so. 
•	 The increased life expectancy of patients with Marfan syndrome has mostly 
been among people of working age; therefore a number of people have 
been able to remain active in the workforce.
academic impacts, and clinical research will pro-
duce more wider impacts on health policy, health 
gain and broader economic benefits. This suggests 
that funding bodies could prioritise basic bio-
medical or clinical research based on the type of 
research impact they wish to achieve and the tim-
escale over which they wish to achieve it.
There is no correlation between 
knowledge production and wider impacts
A further finding on the nature of impact is the lack 
of correlation between knowledge production and 
the three payback categories associated with wider 
impacts (Figure 4.2). As already noted (see Deriv-
ing impact categories section on page 12), there is 
some correlation between knowledge production 
and research targeting and capacity building.
Here it is important to remember our earlier 
caveat about different types of research having 
different impact profiles, and the time lags often 
involved before wider impacts arise. Nevertheless, 
from a policy perspective this finding would sug-
gest that wider impacts are not necessarily predi-
cated on knowledge production and that research Findings, observations and policy implications    27
funding agencies wishing to maximise wider 
impacts should use broader selection criteria, 
rather than relying solely on those associated with 
trying to maximise knowledge production. 
The majority of economic impacts 
identified come from a minority of 
projects
A further important finding relates to broader eco-
nomic impacts (as defined above). Only a small 
number of case studies (4 of 29) showed that 
the projects produced broader economic benefits 
rated 4 or above (Figure 4.3). This means that the 
majority of the economic impacts identified came 
from a minority of projects. That small proportion 
can, however, produce impacts of a very signifi-
Figure 4.2
Correlations between knowledge production and other payback categories. Note that we have slightly 
offset overlapping points, on the vertical axis, so the number of points in any one place can be seen. 
The actual values are all integers.
Figure 4.3
Distribution of broader economic impacts
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rately, therefore the cut points between the high, 
mid and low groups differ. In other words a clinical 
case study that is mid academic impact when all the 
case studies are considered may be high academic 
impact when only clinical case studies are consid-
ered. The shaded histograms (Figures 4.4–4.14) 
show associations that are discussed in the text: 
blue shading represents associations found in basic 
research, red represents clinical research and purple 
shading is used where an association is found irre-
spective of the type of research. As discussed earlier, 
we used the Fisher Exact test to determine whether 
there are non-random associations between the 
variables and interpret the results as providing us 
with a relative indication of the likely robustness of 
our associations (we treat them as indicative because 
of the small sample size and stratified nature of our 
selection). As the p-numbers illustrate, with just 29 
case studies to start with, and each factor based on 
analysis of the subset of the 29, some of the differ-
ences described could have arisen by chance or as a 
result of a correlated but quite different factor: our 
observations should be considered with that caveat 
in mind. 
1. Basic biomedical research with a clear 
clinical motivation is associated with 
high academic and wider impacts
The definition used for this observation was that 
clinically motivated basic biomedical research 
occurs when there is evidence in the case study 
that the research team has a clearly articulated 
clinical endpoint and/or is explicit in the case 
study about their clinical motivation. How far the 
motivational issue overlaps with the PI being a cli-
nician is discussed below, with examples (Figure 
4.4). We observed that clinically motivated basic 
biomedical research is associated with higher 
impacts. All high academic (5/5) and wider (5/5) 
impact case studies on basic biomedical research 
demonstrated a clinical motivation, compared to 
2/6 low academic impact case studies, and 3/6 for 
low wider impact. 
For the five high academic and wider impact 
case studies on basic biomedical research, three 
of the researchers had a clinical qualification, 
although they describe their research as being 
basic biomedical; this is confirmed in our sensi-
tivity analysis of the basic biomedical–clinical 
research definitions in Chapter 2. In such cases 
motivation can be explained by the researchers’ 
cant value – and we know from previous research 
that the value of the impacts of programmes of 
research assessed significantly outweigh the costs, 
resulting in a very attractive return on investment 
(HERG et al., 2008).
As noted above, the definition of broader eco-
nomic benefits we use here is rather restrictive, but 
nevertheless it is interesting to note that the dis-
tribution for broader economic benefit is highly 
skewed. Such a skewed distribution is similar to 
those observed in empirical studies of the pro-
ductivity of authors, and output and citations of 
papers (Erar, 2002). These distributions tend to 
follow the 80:20 rule where, for example, 80% of 
citations come from 20% of papers. From a policy 
viewpoint it is important that these distributional 
effects are understood and acknowledged in any 
assessment and discussion of research impact, 
especially when it could influence the allocation 
of research funds.
Factors associated with impact
As stated earlier, a challenge for research funders 
and policy makers is to identify factors that are 
associated with high or low impact and could be 
used to inform policy and funding decisions. In 
this section we identify a number of factors in 
cardiovascular and stroke research that are associ-
ated with higher and lower academic and wider 
impacts. These factors provide some evidence of 
the characteristics of the research projects most 
likely to create substantial impact. Table 4.4 pro-
vides an overview of all 29 case studies, showing 
which impact groups they belong to and the fac-
tors associated with impact identified in each.
Because our observations are based on a rela-
tively small number of cases, especially when disag-
gregated into various groups for analysis, we always 
quote actual numbers of case studies for numera-
tors and denominators, e.g. 2/3 for 2 out of 3, to 
avoid any impression of spurious precision or gen-
eralisation. For each of the factors being assessed 
we illustrate the associations through a standard set 
of figures, with six histograms cap-turing the rela-
tionship between high-, mid- and low-impact case 
studies by the type of research (all research, basic 
biomedical and clinical) and the type of impact 
(academic and wider). As discussed in Chapter 2, 
ranking all the case studies differs from ranking 
the basic biomedical or clinical case studies sepa-Findings, observations and policy implications    29
Table 4.4
Overview of the 29 case studies indicating impact groups and factors associated with impact identified 
in each
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on basic biomedical research were conducted in a 
clinical setting, compared to 2/6 low-impact case 
studies (and 2/4 mid-impact case studies). Two   
PIs explicitly expressed this point in their case 
studies:
“One of the great things about being here has 
always been that if you wanted to do something 
clinical the people are right here ... So they are 
willing to talk to you ... And they are interested 
in doing research and collaborating.”
“To work in isolation is extraordinarily difficult. 
You just cannot overestimate the value of those 
casual conversations in the coffee room, the 
formal weekly meetings, where you justify your 
position and the progress you are making. And 
the opportunity for informal collaboration …”
By contrast, the same does not apply for academic 
impact for basic biomedical research or for aca-
demic or wider impact for clinical research asso-
ciation. There might be several possible reasons for 
this. We could deduce that co-location can stimu-
late demand for basic biomedical research within 
clinical background, as remarked by a number of 
the principal investigators:
“The product you see is not just a clinician; it 
is a clinician with a strong background in the 
laboratory.”
“I am not a basic science driven person, driven 
by the knowledge of basic science; I am driven by 
an application at the end of the day that has a 
bottom line in terms of clinical practice.”
Policy implication: When seeking to achieve 
high academic and wider impacts, encourage and 
support clinically motivated basic biomedical 
research.
2. Co-location of basic biomedical 
research in a clinical setting is associated 
with high wider impact 
We considered co-location of basic research in 
a clinical setting to have occurred when basic 
research projects were undertaken in a hospital 
or similar setting. As shown in Figure 4.5, the 
majority (4/5) of high wider impact case studies 
Figure 4.4
Clinical motivation
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Figure 4.5
Co-location of research
Figure 4.6
Overlap of clinical motivation and co-location
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3. Strategic thinking by clinical 
researchers is associated with high 
wider impact 
For the purposes of this study, we define strategic 
thinking as the process of thinking used by clini-
cians when there was evidence in the case study 
that the research team had thought through the 
pathways by which research could potentially be 
translated into practice. There is some evidence 
that the thinking through the translation and 
application of clinical research is associated with 
wider impact. All (5/5) high wider impact case 
studies on clinical research had evidence of stra-
tegic thinking by the PI, compared to 1/4 low-
impact case studies (Figure 4.7). 
From a policy perspective, these data suggest 
there are benefits when clinical research is under-
taken by those able and willing to think about its 
potential translation into clinical practice. This 
may have relevance to initiatives to include dis-
cussion of potential translation in research appli-
cations, although it is not clear from our data 
whether encouraging other researchers to think 
through translation would have the same effects.
the clinical sector; or perhaps the clinical location 
helps create a clinical motivation. Seen from the 
perspective of the would-be funder, this suggests 
that co-location is only really beneficial when the 
aim is to translate basic biomedical research into 
wider impacts.
We also investigated the overlap between clini-
cal motivation of basic biomedical research and 
co-location of basic biomedical research in a clini-
cal setting (Figure 4.6). Interestingly this overlap 
only occurred for high-impact case studies. Four 
out of five high wider impact cases studies on basic 
biomedical research demonstrated a clinical moti-
vation and were conducted in a clinical setting, 
compared to no low-impact case studies. This 
would suggest that the two factors act synergis-
tically, although this observation clearly warrants 
further research.
Policy implication:  When seeking to achieve 
high wider impacts from basic biomedical 
research, encourage and support the co-location 
of basic biomedical researchers with clinicians in 
a clinical setting (e.g. a teaching hospital or health 
organisation)
Figure 4.7
Strategic thinking
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(where researchers outside the group contributed 
to the design of the study); and other (types of col-
laboration not captured in the first two categories). 
We examined the case studies for examples of col-
laboration and ways in which it occurred in each 
of these three areas. 
Our analysis revealed that collaboration is never 
strongly associated with low impact, although   
the association with high impact varies from 
strong to none at all (Figure 4.8). The majority of 
high academic impact case studies (7/9) involve 
some type of collaboration, compared to 1/10 low-
impact cases. The most common form of collabo-
ration is resource-based – observed in 20/29 of the 
cases – and only two are with non-researchers, a   
fish hatchery and a care provider. However, of   
all the examples of collaboration in our case   
studies, only resource-based collaborations pro-
duced negative results; if these are excluded, the 
association of high impact with collaboration 
increases.
We found that collaboration is common in 
both clinical and basic biomedical case studies 
but that the association of collaboration with high 
Policy implication: When seeking to achieve 
high wider impacts from clinical research, focus 
clinical research funding on PIs or teams who 
think strategically about translation into clinical 
practice.
4. Research collaboration is associated 
with high academic and wider impact
Collaboration is often seen as an important factor 
for success in scientific research but it can take many 
different forms and operate at a range of levels. It can 
involve collaboration within the national research 
system, with international colleagues, industrial 
partners, policy makers, practitioners or even 
patients themselves. These overlap in various ways, 
but as far as possible we concentrate here on collab-
oration by researchers within the research system, 
while considering other types of collaboration. 
We defined collaboration as activities that 
involved both project team researchers and other 
researchers outside that group. We separated out 
three types of collaboration – resource-based 
(where researchers shared reagents, equipment 
or other research infrastructure); design-based 
Figure 4.8
Research collaboration
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5. International collaboration is 
associated with high academic impact
We defined international collaboration as activi-
ties involving researchers or others based outside 
the country in which the research took place. 
We included case studies where such activities 
occurred or where PIs talked about their attitudes 
towards international collaboration. We consid-
ered two subcategories of international collabora-
tion: where it had facilitated the research process – 
for example, through the modification of research 
protocols; and where it had facilitated impact. 
Overall, international collaboration is associ-
ated with higher academic impact (Figure 4.9). 
Over three quarters of high academic impact case 
studies (7/9) were associated with international 
collaboration compared to 1/10 for low academic 
impact case studies.
International collaboration is also more strongly 
associated with high-impact clinical research than 
with basic biomedical research.
academic impact is much stronger in clinical cases 
than in basic biomedical research. When case stud-
ies that produced negative results were excluded 
from the sample, this relationship between aca-
demic impact and collaboration in clinical research 
was weaker because all the low-impact cases had 
been removed. Nevertheless, there remained suffi-
cient disparity between the high-impact cases and 
the mid-impact cases to support the association 
between high academic impact and collaboration.
The link between collaboration and high 
impact is robust enough to stand up to reclassi-
fication of the case studies; when a disputed basic 
biomedical case study was reclassified as clinical, 
it strengthened the relationship with academic 
impact. Conversely, when a disputed clinical case 
was reclassified as basic biomedical, the relation-
ship was weakened, but was still evident.
Policy implication: When seeking to achieve 
high academic and wider impacts, encourage and 
support research collaboration for both basic bio-
medical and clinical research.
Figure 4.9
International collaboration
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driver in improving the science and influenced 
the way research was done.” 
For basic biomedical research collaboration, facili-
tating research included mentoring and the provi-
sion of particular technical skills or reagents; there 
was no association with higher impact.
5b.	International	collaboration	facilitating	
impact
The subcategory “international collaboration facil-
itating impact” was only identified in three case 
studies and showed no particular association with 
impact.
Overall, our analysis suggests that interna-
tional collaboration is more important in carrying 
out research leading to impact than it is in facili-
tating the impact of research – possibly because 
much of the impact is national rather than inter-
national in nature.
Policy implication: When seeking to achieve 
high academic impact, encourage and support 
international collaboration for both basic biomed-
ical and clinical research.
5a.	International	collaboration	facilitating	
research
The subcategory “international collaboration 
facilitating research” (Figure 4.10) shows an asso-
ciation with high impact that is strongest for aca-
demic impact when all case studies are considered. 
Examples include collaboration with international 
research groups that strengthen research protocols, 
collaborations to bring new techniques into the 
work and collaborations born out of a PI having a 
resource that is helpful to other researchers (such as 
a database of gene mutations). We found that this 
type of collaboration has a strong positive influence 
on academic impact for clinical research projects:
“A further factor that impinged on the design 
of the data collection and reporting was that a 
group of experts met at Utstein Abbey in Norway 
and produced recommendations for standardised 
reporting.”
“For example, all the quality control protocols 
and systems were international. … This 
international collaboration (and the associated 
meetings) was confirmed by [the PI] as a key 
Figure 4.10
International collaboration facilitating research
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and patients was identified, they both achieved a 
high rating for wider impact for basic biomedical 
research, constituting 2/5 such projects. Of the six 
low wider impact and four mid wider impact basic 
biomedical case studies, none were identified as 
having practitioner or patient collaboration.
The associations were weaker when the alterna-
tive methods of classifying basic biomedical and 
clinical cases were applied: two of the clinical high 
impact cases fell into the basic biomedical mid-
impact category.
While most of the evidence gathered about this 
in our case studies specifically relates to engage-
ment after the research has been produced, there 
is evidence that such engagement leads more 
readily to publication in high-profile journals, 
although further work is needed to explore this. 
There is a clear logic underpinning the association 
between researchers whose clinical research has a 
wider impact and their engagement with practi-
tioners and patients. But what is less clear from 
the figures is whether it is the engagement with 
practitioners and patients that helps to generate 
the wider impacts, or whether the wider impacts 
6. Engagement with practitioners 
and patients is associated with high 
academic and wider impacts
We defined engagement with practitioners and 
patients broadly, indicating that the PI had some 
interaction with either group in a way relevant to 
the planning or organisation of the research project, 
or to achieving impacts. We do not mean simply 
involving patients in trials or studies. It became 
clear that a track record of collaboration with prac-
titioners and patients was much more a feature of 
clinical than of basic biomedical research. Ten out 
of 14 clinical case studies showed this kind of col-
laboration, but only 2/15 basic biomedical stud-
ies. However, there is an association between a 
research project’s engagement with practitioners 
and patients and high academic and wider clinical 
impacts. All high academic (6/6) and wider (5/5) 
impact case studies on clinical research involved 
practitioners and patients, compared to 1/4 for low 
academic impact and 2/4 for low wider impact case 
studies. As Figure 4.11 illustrates, we found that 
while there were only two basic biomedical research 
projects where collaboration with practitioners 
Figure 4.11
Engagement with practitioners and patients
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“Formal networks, such as the Canadian Stroke 
Network, have also been a huge help for this 
project in putting the team in touch with other 
collaborators or clinicians who have patients 
with high risk for heart disease or stroke.”
“As a leading clinician in this field, and Medical 
Advisor and Director to the UK patient and 
research organisations, X was well placed to 
provide ‘official’, research-informed advice for 
clinicians and patients.”
From a funding viewpoint, these findings are 
consistent with the claims in the literature that 
researchers who want their work to have some 
influence on policy decisions are more likely to 
be successful if they collaborate in some way with 
practitioners and patients (Innvær et al., 2002; 
Hanney et al., 2003; Denis and Lomas, 2003; 
Conklin et al., 2008).
Policy implication: When seeking to achieve 
high academic and wider impacts, encourage and 
support clinical researchers who have a record of 
engaging with practitioners and patients. 
stimulate practitioner/patient engagement. Of 
course, we should remember that clinicians who 
carry out research are almost inevitably going to 
have engagement with patients and practition-
ers. In that regard it might be surprising that in 
4/14 clinical research projects the case study did 
not identify any engagement with practitioners or 
patients. However, further analysis revealed that 
these four projects were all exploratory or observa-
tional studies looking for markers or associations, 
an approach which need not necessarily involve 
practitioners or patients directly.
Whatever the cause and effect, it is clear 
from various case studies that some researchers   
make considerable efforts to engage with practi-
tioners and patients, promote the impact of their 
research and undertake knowledge transfer. For 
example:
“The more direct impacts were with the clinicians 
working with the researchers and the health 
promotion team and their work with the Hunter 
community and local patient and advocacy 
groups.”
Figure 4.12
Collaboration with industry
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“The PI was also the recipient of large sums of 
funding from a variety of sources over the later 
years of the grant. In particular he won substantial 
support funding from industry in 1995.”
“The PI stated that doing research for the 
pharmaceutical industry often generated 
generous rewards and that at times he has 
applied surpluses from industry funding to his 
stroke research.”
Unlike basic biomedical research, from our study 
there appears to be no clear relationship between 
collaboration with industry and the academic 
impact of clinical research projects; indeed, for 
wider impact the relationship is negative, with 
more low-impact case studies involving collabo-
ration with industry than high-impact ones. We 
do not fully understand this surprising association 
and it warrants further investigation.
Policy implication: When seeking to achieve 
high academic and wider impacts from basic bio-
medical research, encourage and support collabo-
ration with industry. 
7. Basic biomedical research 
collaboration with industry is associated 
with high academic and wider impacts
We defined collaboration with industry as occur-
ring whenever there was clear evidence of the PI or 
a key member of the team working with, or pro-
viding advice to, industry, or where an industrial 
company was identified as providing resources to 
support or facilitate the research. Four out of the 
five basic biomedical projects that received a high 
academic impact rating had evidence of collabo-
ration with industrial partners, compared to 1/6 
low-impact projects. The same number (4/5) of 
basic biomedical projects that were rated high for 
wider impacts had also collaborated with industry, 
compared to 2/6 for low-impact (Figure 4.12).
We believe that this relationship may be the 
result of the access to various additional resources 
that collaboration with industry has provided (see 
the quotes below), although it is quite possible 
that the association works as well in the opposite 
direction and that industry seeks out high-profile 
researchers.
Figure 4.13
Negative or null findings
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constituted 3/10 with low wider impacts, 4/10 
with mid wider impacts and, again, none of those 
with high wider impacts. This is most clearly evi-
dent in clinical research, where we noted that 4/4 
case studies receiving a low academic impact rating 
and 2/4 cases given a low wider impact rating had 
all produced negative or null findings. None of 
the grants producing negative or null findings was 
considered to have had high impact, either aca-
demic or wider.
These results suggest a bias against negative 
or null findings, particularly in academic impact. 
We believe that this is most likely to be attribut-
able to the fact that journals are often unwilling to 
publish papers on research that has delivered such 
findings (Johnson and Dickersin, 2007); similarly, 
researchers may be reluctant to submit these papers 
for publication in the first place, although we note 
that all our case studies produced at least one pub-
lication. It must also be hard to realise impacts for 
research that failed to prove something (as opposed 
to research that proved that something failed).
If there is such a bias, there are two risks asso-
ciated with it: first, that research resources will be 
8. Negative or null findings are 
associated with low academic and wider 
impacts
We defined projects with negative or null find-
ings as those that either failed to support a specific 
hypothesis formulated by the researcher (null find-
ings), or were cut short before the planned work 
was complete, due to initial findings contradict-
ing the accepted viewpoint in the field (negative 
findings). Seven of the 29 case studies had nega-
tive or null findings. The majority (six) of these set 
out to test a specific hypothesis formulated by the 
researcher. The one remaining case study produced 
initial results that contradicted the accepted view-
point in the field, a finding that prevented some of 
the planned subsequent work from taking place.
A clear pattern emerging from our study is that 
negative or null findings in both basic biomedi-
cal and clinical research are associated with low 
impact (Figure 4.13): 7/29 case studies resulted in 
negative or null findings. These seven constituted 
5/10 of the low-impact academic studies, 2/10 of 
the mid-impact academic studies, and none of the 
high-impact academic studies. Similarly the seven 
Figure 4.14
Initial rejection of grant application
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wasted by others duplicating the same negative or 
null results; second, that clinical practice may con-
tinue with things that do not work.
Evidence from one case study suggests that, in 
addition to contributing little in terms of knowl-
edge production, negative findings may also have 
had a negative impact in research targeting and 
capacity building. One PI noted that a PhD stu-
dent on the grant: 
“would have struggled to find a good position 
in academia had he wanted to stay, due to the 
negative findings of the project … and through no 
fault and no reflection on his research quality.” 
We should also be aware that there may have been 
some bias in our method, perhaps unavoidably 
so. In particular, it is easier to conceptualise and 
estimate impact of things that did happen than of 
things that did not.
Policy implication: Research funders should 
acknowledge the importance and potential signifi-
cance of negative or null findings when assessing 
the impact of research.
9. Initial rejection of a subsequently 
accepted basic biomedical research grant 
may be associated with low academic 
and wider impacts
This is a novel observation that, as far as we are 
aware, has not been made in the literature and 
needs further investigation. We found that the 
initial rejection of a research proposal followed 
by its acceptance by a funding body was relatively 
uncommon (occurring in 5/29 cases). Of six basic 
biomedical studies, 3/6 with low wider impact 
had initially been rejected compared to 0/4 in the 
mid category and 0/5 with high academic impact 
(Figure 4.14). 
Three of the five initially rejected case studies 
were on basic biomedical research and all three 
were UK cases. The remaining two projects ini-
tially rejected were clinical, one from the UK and 
one from Australia. At least 3/5 initially rejected 
projects were revised to make them smaller, or 
more focused, before being re-submitted for fund-
ing and all five were re-submitted to a different 
funder.
“An initial application for funding, made to 
the Medical Research Council (MRC) was 
unsuccessful despite being awarded an ‘alpha’ 
for its scientific content. The applicants then 
re-formulated the proposal to make it more 
specific to cardiovascular disease, before 
submitting it to the X.”
One possible explanation may be that proposals 
that are initially rejected by review committees 
indicate a flaw or concern in the research that is 
carried through in a re-application and ultimately 
into its academic and wider impacts. What is not 
clear is why the subsequent acceptance of an ini-
tially rejected proposal is disproportionately prev-
alent in the UK. 
Policy implication: Further research is needed 
to confirm whether initial rejection of a research 
proposal is associated with low impact. Until this 
finding can be confirmed or refuted, funders may 
want to carefully consider such proposals.
Concluding thought
This report identifies some key factors that appear 
to be related to research impact and successful 
translation, which were discussed above and are 
summarised in Table 4.5, although it is clear there 
is much more to be discovered. Our observations, 
and the policy implications that they raise, ought 
to make policy makers think more deeply about 
the research they fund and provide some evidence 
to improve their decision making. As we noted at 
the outset, this study clearly does not answer all 
the questions about how to fund research and we 
look forward to other studies that build under-
standing in this area.Findings, observations and policy implications    41
Table 4.5
Factors associated with high- and low-impact research 
Factor Evidence Policy implication 
Basic biomedical research 
with a clear clinical 
motivation is associated 
with high academic and 
wider impacts
All high academic (5/5) and wider impact 
(5/5) case studies on basic biomedical 
research demonstrated a clinical 
motivation, compared to 2/6 low academic 
impact case studies, and 3/6 for low wider 
impact.
When seeking to achieve high 
academic and wider impacts, 
encourage and support clinically 
motivated basic biomedical research.
Co-location of basic 
biomedical research in a 
clinical setting is associated 
with high wider impact
The majority (4/5) of high wider impact 
case studies on basic biomedical research 
were conducted in a clinical setting, 
compared to 2/6 low wider impact case 
studies.
When seeking to achieve high wider 
impacts from basic biomedical 
research, encourage and support 
the co-location of basic biomedical 
researchers with clinicians in a clinical 
setting (e.g. a teaching hospital or 
health organisation).
Strategic thinking by clinical 
researchers is associated 
with high wider impact 
All high wider impact (5/5) case studies on 
clinical research had evidence of strategic 
thinking by the PI, compared to 1/4 low 
wider impact case studies.
When seeking to achieve high wider 
impacts from clinical research, focus 
clinical research funding on PIs or 
teams who think strategically about 
translation into clinical practice.
Research collaboration 
is associated with high 
academic and wider impact
The majority (7/9) of high academic 
impact case studies involve some type of 
collaboration compared to 1/10 academic 
low-impact case studies.
When seeking to achieve high 
academic and wider impacts, 
encourage and support research 
collaboration for both basic 
biomedical and clinical research.
International collaboration 
is associated with high 
academic impact
Over three quarters of high academic 
impact case studies (7/9) were associated 
with international collaboration, compared 
to 1/10 low academic impact case studies.
When seeking to achieve high 
academic impact, encourage and 
support international collaboration 
for both basic biomedical and clinical 
research.
Engagement with 
practitioners and patients 
is associated with high 
academic and wider 
impacts
All high academic (6/6) and wider impact 
(5/5) case studies on clinical research 
involved practitioners and patients, 
compared to a quarter (1/4) for low 
academic impact and a half (2/4) for low 
wider impact case studies.
When seeking to achieve high 
academic and wider impacts, 
encourage and support clinical 
researchers who have a record of 
engaging with practitioners and 
patients.
Basic biomedical research 
collaboration with industry 
is associated with high 
academic and wider 
impacts
In basic biomedical research, the majority 
of high academic (4/5) and wider impact 
(4/5) case studies had evidence of 
collaboration with industrial partners, 
compared to 1/6 low academic impact and 
2/6 low wider impact case studies.
When seeking to achieve high 
academic and wider impacts from 
basic biomedical research, encourage 
and support collaboration with 
industry.
Negative or null findings 
are associated with low 
academic and wider 
impacts
7/29 case studies resulted in negative 
findings. These 7 constituted 5/10 of the 
low-impact academic studies, 2/10 of the 
mid-impact academic studies, and none 
of the high-impact academic studies. 
Similarly the 7 constituted 3/10 with low 
wider impacts, 4/10 with mid wider impacts 
and, again, none of those with high wider 
impacts.
Research funders should 
acknowledge the importance and 
potential significance of negative 
or null findings when assessing the 
impact of research.
Initial rejection of a 
subsequently accepted basic 
biomedical research grant 
may be associated with 
low academic and wider 
impacts
Initial rejection of a subsequently accepted 
research proposal was uncommon (5/29) 
but associated with low wider impact for 
basic biomedical research. 3/6 low wider 
impact case studies on basic biomedical 
research had initially been rejected, 
compared to 0/5 high-impact case studies. 
Further research is needed to 
confirm whether initial rejection 
of a research proposal is associated 
with low impact. Until this finding 
can be confirmed or refuted, funders 
may want to consider such proposals 
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